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Hypoxia is a hallmark of several solid tumors and it is often associated with chemotherapy 
resistance. The O2 levels decrease induces the activation of Hypoxia-inducible factor 1 (HIF-1) 
which coordinates cellular adaptive changes and metabolic reprogramming. This heterodimeric 
transcriptional factor is considered as a master regulator of hypoxic cellular response and plays key 
roles in development, physiology and disease. Under normoxic conditions, HIF-1α subunit has a 
high turnover strictly regulated by the activation of prolyl hydroxylases (PHDs). At low oxygen 
levels, PHDs activity is inhibited and HIF-1α is stabilized and migrates into the nucleus where it 
bounds the HIF-1β and exerts its transcriptional activity.  
Our research group has demonstrated that the lack of respiratory complex I (CI) imbalances the α-
ketoglutarate (αKG)/succinate (SA) ratio towards αKG, metabolites that regulate the PHDs activity. 
The chronic activation of PHDs leads to HIF-1α destabilization even when O2 is available, a 
condition that we termed pseudonormoxia, and hampered tumor growth in vitro and in vivo. 
We hypothesized that pseudonormoxia may be induced by unbalancing the αKG/SA ratio 
mimicking a normoxic condition and leading to the block of tumor progression. In this context, the 
aim of this PhD project was to prove that HIF-1α destabilization and pseudonormoxia can be 
pharmacologically induced by increasing αKG levels using CI inhibitors (indirect approach) or cell 
permeable αKG ester derivatives (direct approach) in order to identify novel and safe adjuvant 
therapeutic agents for aggressive cancers. We screened a panel of compounds, composed by 
molecules that potentially may act as CI inhibitors and seven αKGlogues, for their ability to 
specifically destabilize HIF-1α in cancer cells, while being not toxic for their non-cancer 
counterpart. From these experiments, we identified four promising compounds that fit these criteria 
and that will be used for further investigations. The link between HIF-1α stabilization and 
mitochondrial function opens to new metabolic-based therapeutic approaches for cancers for which 












Hypoxia as a drive force of solid tumor malignancy.  
The maintenance of adequate oxygen levels is required to sustain physiologic cellular functions 
1
. 
However, a reduction of oxygen availability, also known as hypoxia (0.05-5% O2), often represents 
a condition that can be limited to some cells within a tissue, to certain tissue belonging to specific 
organs or involving the whole organism. The effect of hypoxia can be more or less severe, 
depending on the O2 levels, duration and context 
2
. During fetal development, hypoxia represents a 
positive, necessary stimulus, required for the appropriate growth and function of certain organs 
3
. 
Indeed, a gradient in the oxygen tension across the tissue is required for the physiologic function of 
some organs 
4
. Over the long-term, hypoxia is not usually compatible with normal cell function and 
therefore multicellular organisms have evolved both systemic and cellular responses to inadequate 
oxygen tension. In this context, the oxygen shortage is related to several pathologies, such us 
myocardial and cerebral ischemia, diabetes, neurodegeneration and cancer 
5, 6, 7
. Indeed, a common 
feature of most solid tumors is the ability to adapt to low O2 levels, even anoxia (≤ 0.01% O2) 
8, 9
. 
The high proliferative rate of cancer cells and growing tumor mass imply that tumor cells often 
have restricted access to nutrients and oxygen. Most solid tumors are characterized by the presence 
of regions permanently or transiently subjected to hypoxia due to aberrant vascularization and a 
poor blood supply promoting the formation of hypoxic niches 
10
. Tumor cells in these regions begin 
to adapt to low oxygen tension by activating several survival pathways mainly mediated by the 
transcriptional activation of the hypoxia-inducible factor 1 (HIF-1), which is considered the key 
regulator of cell hypoxic response by modulating the expression of hundreds of genes involved in 
glycolytic metabolism, angiogenesis and cancer cell survival 
11, 12 
(Figure 1). Under hypoxic 
conditions, cancer cells are constrained to switch their metabolism from oxidative to glycolytic and 
enhance their ability to generate ATP by increasing glucose uptake. In this context, HIF-1 is 
responsible for the up-regulated expression of glycolytic enzymes and glucose transporters 
(GLUTs) 
13
.  Active HIF-1 also promotes angiogenesis through the transcriptional induction of 
several pro-angiogenic factors, including the vascular endothelial growth factor (VEGF) which is 
considered the most potent endothelial-specific mitogen by recruiting endothelial cells into hypoxic 
areas and stimulating their proliferation 
14
. In addition, HIF-1 promotes the migration of tumor 
metastasis into distant and more oxygenated tissues by activating the transforming growth factor-β3 
(TGF-β3), epidermal growth factor (EGF) and others 
15
. In this scenario, HIF-1 is considered as one 







Figure 1: Involvement of HIF-1 and their targets in different aspects of cancer 
16
. The HIF-1 activity has been 
implicated in promoting angiogenesis, invasion/metastasis, proliferation, glycolysis, therapeutic resistance, 
inflammation, and immune evasion.  
 
 
HIF-1 structure and its involvement in cancer cells adaptation to hypoxia. 
HIF is a heterodimeric transcription factor consisting of an oxygen sensitive α-subunit and a 
constitutively expressed β-subunit. In human cells has been identified three paralogs of HIF-α (HIF-
1α, HIF-2α, HIF-3α) and two paralogs of the HIF-β subunit (ARNT, ARNT2). HIF-1α and HIF-2α 
are very similar structurally and better characterized compared to HIF-3α, which seems to inhibit 
HIF-1α and HIF-2α activity in a dominant-negative fashion 
17
. These last two α subunits differ in 
their transcriptional domains and may therefore bind different co-factors and affect the expression 
of different genes 
18
. Furthermore, HIF-1α is ubiquitously express in all cells, whereas HIF-2α and 
HIF-3α are preferentially expressed in specific tissue 
19
. However, all HIF-α subunits can 
heterodimerize with both β-subunits. ARNT2 has a more limited tissue distribution but dimerizes 





Both α and β subunits belong to the basic Helix-Loop-Helix-Per-Arnt-Sim (bHLH-PAS) protein 
family 
21
. The bHLH-PAS domain is necessary for the heterodimerization between α and β subunits 
and for the subsequent recognition and binding with Hypoxia Response Element (HRE) sequence, 
present in the promoters of the HIF-1 target genes 
22
 (Figure 2). HIF-1α contains two transactivation 
domains located respectively in the N-terminal and C-terminal of the protein, named N-TAD and C-
TAD 
23
. In particular, the C-TAD domain interacts with the transcriptional coactivators p300/CREB 
through the hydroxylation of asparagine 803 (Asn803), while proline 564 and 402 (Pro564 and 
Pro402) in the oxygen dependent degradation domain (ODDD) mediate the recognition of HIF-1α 
by von Hippel-Lindau tumor suppressor protein (pVHL) 
24, 25, 26
 (Figure 2). These prolines are 
essential for the regulation of HIF-1α abundance in response to changes of oxygen tension. Under 
normoxic conditions (21% O2), HIF-1α is hydroxylated on Pro402 and Pro564 by prolyl 
hydroxylases (PHDs), which are members of the Fe(II)/α-Ketoglutarate (αKG)-dependent 
dioxygenase enzyme family 
27
. The hydroxylation of these conserved residues triggers the VHL-
mediated ubiquitination and consequent proteasomal degradation of HIF-1α subunit 
28
. In parallel, 
Asn803 is hydroxylated by the factor inhibiting HIF-1 (FIH-1), another Fe(II)/αKG-dependent 
dioxygenase as PHDs, that binds to HIF-1α and inhibits its transactivation function blocking its 
interaction with the coactivators p300/CREB 
29
. Conversely, under hypoxic condition (0.05-5% O2), 
PHDs activity is inhibited preserving HIF-1α stability, which translocate into nucleus and dimerizes 




Figure 2: Domain structure of HIF-1α and HIF-1β subunits (adapted image) 
30
. Schematic representation of HIF-
1α (826 amino acids) and HIF-1β (789 amino acids). The N-terminal of both subunits consists of basic helix-loop-helix 
(bHLH) and Per-Arnt-Sim homology domains (PAS) that are required for heterodimerization and DNA binding, 
respectively. HIF-1α possess an oxygen-dependent degradation domain (ODDD) required for oxygen-dependent 
hydroxylation and degradation. The C-terminal region of HIF-1α contains two terminal-transactivation domains 
(TADs), which are separated by an inhibitory domain (ID). The transcriptional activity of the C-TAD domain is 
associated with the binding of transcriptional co-activators, including the p300/CREB. HIF-1α is potentially 
hydroxylated at two proline residues (Pro), which induces binding of von Hippel–Lindau protein (pVHL). 
Hydroxylation of an asparagine residue (Asn) located in the C-TAD of HIF-1α inhibits their interaction with 
p300/CREB. NLS, nuclear localization signal.  
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The stability and activity of HIF-1α is strictly regulated by PHDs (Figure 3). In humans, three 
different isoforms of these enzymes have been identified (PHD1, PHD2 and PHD3); isoform 2 
seems to be the one mainly involved in HIF-1α regulation 
31
, while the other two preferentially 
regulate HIF-2α stability 
31, 32
. PHDs catalyze the transfer of one oxygen atom from the substrate O2 
to the ketonic carbon of αKG and the second oxygen atom on the proline residues of HIF-1α, 
forming the hydroxyl group. These enzymes require αKG as co-substrate and Fe(II) as cofactor for 
their catalytic activity. In parallel to the hydroxylation reaction, αKG undergoes to decarboxylation 
to form succinic acid (SA) and CO2. Fe(II) is coordinated in the catalytic site of PHD by two 
histidine and one aspartate residues oxidizing in Fe(III) after the interaction with PHD substrates 
and co-substrates. Ascorbate acts as reducing agent keeping iron in the active site in the reduced 
state 
28
 (Figure 3). Most importantly, the relatively high Km of PHDs for O2 is slightly above its 
atmospheric concentration (Km=230-250μM), such that O2 is rate limiting for enzymatic activity 







Figure 3: PHDs mediate HIF-1α stability 
34
. In normoxia, HIF-1α is hydroxylated on two conserved proline residues 
by PHDs, triggering pVHL-mediated ubiquitination and proteasomal degradation. The hydroxylation reaction is 
coupled with the conversion of αKG to succinate and requires co-factors ascorbate and iron. In hypoxia, the enzymatic 
activity of PHDs is inhibited and HIF-1α dimerizes with the constitutively expressed HIF-1β forming the heterodimeric 






At the same time, the Km for αKG is ∼50 μM therefore close to its physiological concentration. 
Thus, besides intracellular O2 levels, even modest variation of αKG concentrations may interfere 
with PHDs activity leading to profound modifications of cancer cells metabolism 
33, 35, 36
. In line 
with this, our group demonstrated that the imbalance of αKG/SA ratio, towards αKG, was related to 
the NADH accumulation, due to the inhibition of αKG dehydrogenase, in respiratory Complex I 
(CI)-deficient cells. Growing levels of αKG lead to a chronic PHDs activity and constitutive 
destabilization of HIF-1α even in hypoxic environment. This profound metabolic alteration induces 
a condition defined pseudonormoxia which humper tumor growth in vitro and in vivo 
37, 38, 39, 40
. In 
this context, the use of specific CI inhibitors or the direct unbalance αKG/SA levels may be adopted 
as a pharmacological strategy to induce a chronic PHDs activity in HIF-1 dependent cancer cells in 
order to mimic a normoxic condition and to induce the arrest of tumor progression.  
 
The effect of oncometabolites on HIF-1α stability in cancer. 
Besides intracellular oxygen levels, also a great number of additional cellular players and molecular 
pathway may concur to regulate HIF-1α stability 
34
. Concerning its PHD-mediated degradation, it 
was demonstrated that also modest variations of αKG concentrations may interfere with PHDs 
activity based on the fact that the Km of αKG for many dioxygenases is similar to the physiological 
concentration of this ketoacid 
35, 36
. In this scenario, several tricarboxylic acid (TCA) cycle 
metabolites are able to interfere with HIF-1α stability through the allosterically competition with 
αKG to modulate PHDs activity, independently from intracellular O2 tension. 
The accumulation of SA, fumarate and 2-hydroxyglutarate (2-HG) have been reported in multiple 
type of cancers harboring respectively succinate dehydrogenase (SDH), fumarate hydratase (FH) 
and isocitrate dehydrogenase 1 and 2 (IDH1/2) mutations. Generally, increased levels of SA and 
fumarate occur as result of the loss of SDH and FH gene function, respectively. Conversely, for 
IDH, a single-allele mutation confers a gain of function producing an excess of 2-HG metabolite 
41
.  
SDH, besides a TCA cycle enzyme, is also the complex II of mitochondrial respiratory chain. Its 
role consists to oxidize SA to fumarate transferring one electron to ubiquinone. It is composed by 
four different subunits, each of which can be mutated causing SDH loss of function 
42, 43
. 
Conversely, FH catalyzes the hydration reaction of fumarate to malate and, as for SDH, loss of 
function has been identified in hereditary forms of leiomyomatosis, renal cancer and childhood 
encephalopathies 
44
. IDH is another TCA cycle enzyme which mutations has been related to 
tumorigenesis 
45, 46
. Three isoforms of IDH (IDH1, IDH2, IDH3) have been already identified. 
IDH1 and IDH2 convert isocitrate to αKG by oxidative decarboxylation, with the production of 
NADPH from NADP
+
 in the cytosol and mitochondria, respectively. The TCA cycle enzyme IDH3 
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is structurally different from the other two isoforms and utilizes NAD
+
 to produce αKG and NADH 
41
. Interestingly, IDH3 has not be found mutated in any cancer until now, whereas mutations in 
IDH1/2 has been associated to loss of enzymatic function to decarboxylate isocitrate and, at the 
same time, also result in a gain of function for the NADPH-dependent reduction of αKG 
41
.  The 
altered activity of IDH1/2 causes an increased affinity for αKG leading to the utilization of NADPH 
in a partially reversed reaction to produce an excess of new metabolite, 2-HG 
41
. The structure of 2-
HG, differently from αKG, is characterized by the presence of one hydroxylic group instead of the 




Figure 4. Similarity of oncometabolites structure 
47
. SA, fumarate and 2-HG are closely linked, both structurally and 
metabolically, to αKG. SA and fumarate differ from αKG only by the presence of a hydroxyl group on C2 and the loss 
of C1. In addition, SA and fumarate differ from each other’s only by the presence of an ethylenic bond, which may 
explain their similar tumorigenic effects. 2-HG differs from αKG only by the presence of a hydroxyl group instead of a 
ketone group.  
 
 
Increased levels of SA, fumarate and 2-HG, as consequence of SDH, FH and IDH1/2, influence 
HIF-1α stability through the modulation of PHDs activity since they share a structurally similar 
with αKG (Figure 4). In particular, SA and fumarate are allosterically competitor of αKG and their 
intracellular higher levels chronic inhibit PHDs activity leading to the stabilization of HIF-1α and 
activation of downstream hypoxic pathways, even in normoxia (i.e. pseudohypoxia) 
48, 49, 50
. On the 
other hand, increase of αKG intracellular levels is sufficient to oppose SA and fumarate effect in 
SDH and FH-deficient tumors leading to the constitutive HIF-1α destabilization 
51, 52
. Hence, the 
levels of αKG, even in hypoxia, may be sufficient to foster PHDs activity and prevent the hypoxic 
response. On the other hand, the metabolite 2-HG probably acts as competitor inhibitor of αKG 
8 
 
occupying its binding site 
53
, but the effect exerted by the accumulation of 2-HG on PHDs activity 
is still debated 
50
. The discovery that higher levels of these TCA cycle metabolites may play a 
primary role to induce metabolic alteration in cancer cells highlights their ability to act as oncogenic 
signaling molecules, being defined oncometabolites 
54
.  
Cancer cells are often characterized by epigenetic, as well as metabolic, alterations. In fact, in many 
types of cancer the genome is affected by the reduction of DNA demethylation and the 
hypermethylation of CpG islands in specific promoter regions compared to the corresponding 
normal tissue. This condition is associated with worse prognosis, potentially due to a silencing of 
tumor suppressor genes 
55
. Recent studies have highlight that oncometabolites may also be involved 
in the alteration of the epigenetic landscape of cancer cells. Increased SA levels inhibit Ten-Eleven 
Translocation proteins (TETs), enzymes involved in DNA demethylation, leading to CpG island 
hypermethylation and also causes the inhibition of Histone Lysine Demethylases (KDMs), involved 
in histone demethylation 
56, 57
. Both TETs and KDMs belong to the αKG-dependent dioxygenase 
family and, for this reason, their activity may allosterically affect by SA intracellular levels. 
Interestingly, DNA hypermethylation is related to dedifferentiation and enhanced tumorigenic 
potential in SDH-deficient tumors 
58, 59
. Similarly, it has been demonstrated that also fumarate and 
2-HG can promote alterations in DNA and histone methylation supporting tumorigenesis 
56, 58, 60
. 
Studies in vitro have revealed that in SDH-deficient tumors the exogenous administration of αKG 
may restore the TETs enzyme activity inhibited by SA restoring the normal cell phenotype 
58
. In 
contrast to genetic mutations, epigenetic modifications are reversible process, offering the 
possibility of the introduction of new therapies for the treatment of certain tumors 
61
.  
αKG a metabolite with pleiotropic activity. 
αKG is a metabolite of TCA cycle derived from the oxidative decarboxylation of isocitrate 
catalyzed by IDH3 and it can be further converted to form succinyl-CoA by αKG dehydrogenase 
enzyme 
62
 (Figure 5). The NAD
+
/NADH ratio plays a crucial role to determine the amount of αKG 
produced in mitochondria. In fact, an accumulation of NAD
+
 promotes the oxidative 
decarboxylation of αKG to succinyl-CoA, conversely the unbalance toward NADH triggers the 
reductive transamination of αKG to form glutamate through glutamate dehydrogenase reaction. 
Glutamate formed in this reaction can be then converted in glutamine 
63
 (Figure 5). Moreover, αKG 
can be generated as a product of pyridoxal phosphate-dependent trans-amination reactions in which 
glutamate is a common amino donor. This TCA cycle metabolite, as others, can penetrate into the 
cytoplasm, where it is used as precursors for biosynthetic reactions. αKG can be transported across 
the inner mitochondrial membrane through the oxoglutarate carrier, also known as an 
9 
 
oxoglutarate/malate antiporter, and subsequently pass through channels (such as voltage-dependent 
anion channels) located in the outer mitochondrial membrane 
64, 65
. 
αKG is often defined as a metabolite with pleiotropic activity since it plays a key role in multiple 
metabolic and cellular pathway. Cataplerotic reactions prevent an accumulation of αKG providing 
to the production of two amino acids, as glutamate and glutamine, that have a crucial role in many 
metabolic pathways. In this context, αKG as intermediate in biosynthesis of these two amino acids 
stimulates protein synthesis, inhibits protein degradation in muscle, constitutes an important 
metabolic fuel for cells of the gastrointestinal tract and determines proper functioning of organs 








Figure 5: Overview of biochemical reactions involving αKG 
67
. αKG have a central role in cellular pathways like 
glutaminolysis or reductive carboxylation of glutamine. Mutant IDH1 changes the dynamics of metabolic processes in 
the cell and leads to accumulation of 2-HG, which in turn inhibits Jumonji domain-containing histone demethylases 




Additionally, exogenous αKG administration may affect the level of histones and DNA methylation 
trigging epigenetic changes. Accordingly, embryonic stem cells (ESC) are characterized by elevated 
αKG/SA ratio that promote histone and DNA demethylation and maintain pluripotency 
68
. In vitro 
studies have shown that cell-permeable αKG directly supports ESC self-renewal, while increased 
levels of SA promotes differentiation suggesting the contribution of proper αKG and SA levels to 
the maintenance of cellular identity by modulate the epigenetic state of stem cells 
68
.  
Moreover, αKG could also act as signaling molecule by acting as ligands for GPR99, a G protein-
coupled receptor 
69
. The activation of this pathway in involved in intracellular Ca
2+
 mobilization 
(via activation of phospholipase C), which acts as a diffusible second messenger regulating a wide 




A recent study has shown that the supplementation of αKG can extend the lifespan of adult 
Caenorhabditis elegans by inhibiting ATP synthase. The inhibition by αKG of this enzyme, also 
known as complex V of the mitochondrial electron transport chain, is related to reduced ATP 
content, decreased oxygen consumption and increased autophagy in both Caenorhabditis elegans 
and mammalian cells 
71
. Such moderation of ATP synthesis induced by TCA cycle metabolite may 
be evolved to ensure energy efficiency in response to nutrient availability. Chin et co-workers 
suggested that this system may be exploited to confer a dietary restriction-like state that favors 
maintenance over growth, and thereby delay ageing and prevent age-related diseases 
71
. 
Interestingly, physiological increases in αKG levels have been reported in starved yeast and bacteria 
and in humans after physical exercise 
72, 73
. In this context, the accumulation of αKG in starved 
condition appears to be a consequence of increased glutamine metabolism to sustain anaplerotic 
gluconeogenesis from amino acids catabolism 
73
. These findings suggest a model in which αKG is a 
key metabolite mediating lifespan extension by starvation/dietary restriction. 
Metabolism is closely linked with ageing. Same of the main consequences of ageing, among others, 
are genomic instability, telomere shortening, epigenetic changes, decreased nutrient sensing and 
altered metabolism 
74
. Given its metabolic properties, αKG may be useful in reducing this type of 
disorders. Moreover, altered metabolism is also a feature of cancer cells 
75
. In the last years, several 
evidences have shown that the mitochondrial genes encoding for Krebs cycle enzymes may 
function as oncogenes or tumor suppressors by influencing different cellular processes. 
As already described, gene encoding SDH and FH might also act as tumor suppressor, while 
IDH1/2 gene products could act as oncogenes 
43, 44, 49, 76, 41
. Thus, mutations in these enzyme support 
cancer progression by inhibiting the activity of αKG-dependent dioxygenase enzymes, such as 
PHDs, TET, and KDM, and in this way they participate in the pathogenesis of many cancers. In this 
11 
 
scenario, exogenous administration of αKG could be used for the reactivation of αKG-dependent 
dioxygenase family proteins and to reverse metabolic and epigenetic alterations in cancer cells. 
Anti-cancer property of exogenous αKG. 
It is demonstrated that exogenous administration of αKG alone or in combination with 
chemotherapeutic agent exhibits anti-tumor activity by inhibiting the HIF-1α subunit expression. 
This is related to the inhibition of tube formation in in vitro angiogenesis models and with a 
reduction of tumor growth and angiogenesis in tumor tissues transplanted in mice 
77, 78
. In these 
studies, the inhibition of HIF-1α expression, promoted by increased αKG levels, induces a reduction 
of Vegf gene promoter activity and, consequently, inhibits VEGF and erythropoietin transcription 
77
. 
Furthermore, others experimental data support the possibility to use αKG in treatment of neoplastic 
diseases in which Krebs cycle enzyme defects cause the chronic activation of HIF-1 even under 
normoxic condition (pseudohypoxia). Brière and colleagues have demonstrated that administration 
of exogenous αKG prevents the translocation of HIF-1 into nucleus of fibroblasts carrying mutation 
in SDHA gene 
79
. In another study, it is shown that the competitive inhibition of PHDs by SA or 
fumarate may be reversed by increasing the cellular level of αKG in SDH- and FH-deficient cancer 
cells opposing to hypoxia mediated activation of HIF-1α 
51
. Since αKG is a hydrophilic metabolite, 
to allow the ketoacid to efficiently penetrate and accumulate into cells MacKenzie and colleagues 
have synthetized cell-permeating αKG derivatives, i.e. αKG esters with increased hydrophobicity 
named octyl-αKG and 1-trifluoromethyl benzyl-αKG (TαKG) which were converted to the free 
αKG form by cytoplasmic diesterases (Figure 6). These derivatives, by restoring PHDs activity in 
such tumors, not only induced HIF-1α destabilization, but also enhanced glycolysis and cell death 
51
. A subsequent study has shown that TαKG derivative was able to penetrate and destabilize HIF-
1α by promoting PHDs activity also in human colon cancer spheroids models, although this 
compound only provided a transient increase of intracellular αKG levels 
52
. Thus, in the same work, 
Tennant and colleagues ethylated the free carboxylic group of TαKG to form a diester ETαKG (1-
trifluoromethylbenzyl, 5-ethyl-αKG) to make it more stable in aqueous solution, with a reduced 
degradation observed after 2 hours 
52
. Intriguingly, the treatment of SDH-deficient xenograft tumors 
with diester form of αKG can reactivate PHDs and destabilize HIF-1α in vivo 
52
. 
Overall, treatment with exogenous αKG may represent an explorable metabolic approach to humper 
tumor growth by inducing a pseudonormoxic state in hypoxic cancer cells. Indeed, the strategy to 
target the PHDs could potentially affect multiple aspect of hypoxic cancer cells, as glycolytic 
metabolism, angiogenesis, increased aggressiveness, by reversing a greater number of pro-
tumorigenic hypoxic phenotypes. In this scenario, the use of αKG analogues will progressively 
12 
 




Figure 6: The αKG can be conjugate to different hydrophobic carriers to increase its permeability across the 
plasma membrane (adapted image) 
80
. Cell-permeating αKG esters allow the ketoacid to cross the plasma membrane. 





The inhibition of respiratory CI activity as indirect approach to increase endogenous αKG 
levels. 
The abundance of αKG in the cell is also dependent to αKG dehydrogenase activity. Indeed, αKG 
can be decarboxylated to form succinyl-Coenzyme A (succinyl-CoA) and CO2 reducing the 
pyridine nucleotide NAD
+
 to NADH. Besides αKG, the enzymatic reaction requires also CoA as 
substrate and thiamine pyrophosphate as a cofactor. The αKG dehydrogenase represents a key 
control point of TCA cycle since it has a downstream regulatory effect on OXPHOS activity and 
ATP production by controlling the amount of available reducing equivalents (such as 
NAD
+
/NADH) generated by the Krebs cycle 
81
. As one of the products of αKG decarboxylation 
reaction, accumulation of NADH may inhibit αKG dehydrogenase activity leading to growing 
intracellular αKG levels 
82
. In this scenario, the αKG dehydrogenase function is strictly 
interconnected with respiratory CI activity. The latter is the first and larger enzyme of 
mitochondrial respiratory chain and catalyzes NADH oxidation to generate the electrochemical 
gradient by feeding the electron transport chain to generate ATP, making NADH an essential 
substrate for oxidative metabolism 
83, 84, 85
. The impairment of CI function is related to the 
unbalance of NAD
+
/NADH ratio, which in turn contributes to inhibit αKG dehydrogenase activity 
increasing αKG endogenous levels 
37, 38, 40, 81
. In this light, inhibited CI activity may indirectly 
promote the induction of pseudonormoxia in HIF-dependent cancer cells. 
The impairment of respiratory CI activity modulates different facets of cancer progression. 
Respiratory CI, also known as NADH:ubiquinone oxidoreductase, is the first component of electron 
transport chain and can be imagined as a hard-working machine that promotes the oxidation of 
NADH, produced through the TCA cycle, and simultaneously the proton translocation across the 
inner membrane, contributing to the generation of the mitochondrial membrane potential needed for 
ATP production 
85
 (Figure 7). CI has a characteristic L-shaped structure that consists of one 
hydrophobic harm embedded into the inner membrane and a hydrophilic arm facing mitochondrial 
matrix 
86
. It is possible to distinguish three functional and structural modules: the N-module 
responsible for the NADH binding and oxidation, the Q-module which allows the electron transfer 
to ubiquinone and the P-module involved into proton pumping in the mitochondrial intermembrane 
space 
87
. CI is composed by 44 subunits, seven of which are codified by the mitochondrial DNA 
(mtDNA), while others 37 subunits are encoded by the nuclear DNA (nDNA) and subsequently 
imported into mitochondria. All subunits must be assembled through a coordinated and finely 
regulated process in order to form the functional enzyme. Several chaperon proteins take part to this 
process and are necessary for the correct assembly 
88
. Considering the crucial role of respiratory CI 
14 
 
and the complexity of its structure and function, it is not surprising that alterations in its activity are 





Figure 7: CI structure and enzymatic activity 
89
. This enzyme promotes the transport of electrons from NADH to 
Coenzyme Q (ubiquinone) and proton transport through the inner mitochondrial membrane. This process allows 4 
protons to be pumped from the mitochondrial matrix into the intermembrane space. CI shows a peculiar L-shaped 
structure which consists of one hydrophobic harm embedded into the inner membrane and a hydrophilic arm facing 
mitochondrial matrix. It is composed of three functional and structural modules: the N-module, Q-module and P-
module responsible for the NADH binding and oxidation, the ubiquinone reduction and the proton translocation in the 
mitochondrial intermembrane space, respectively.  
 
 
Several studies have highlighted the necessity of mitochondrial respiratory function to promote 
tumorigenesis, metastasis migration and escape from dormancy of cancer cells 
90, 91, 92
. For many 
years, a growing number of works reported altered expression or mutations in both nDNA and 
mtDNA-encoded CI subunits in different types of tumors and their role in the modulation of tumor 
progression has been widely debated. Now it is known that impairment of CI activity may plays 
double-edged role in cancer since the severity of dysfunction strongly influences tumor progression, 
metastasis formation and therapy resistance 
93
. Mutations that completely abolish CI activity or 
assembly prevent tumor progression, while mild CI dysfunction may increase intracellular ROS 





The double edge role of CI subunits mutations in cancer.  
Mutations and altered expression of both mitochondrial and nuclear encoded CI subunits may 
concur to impair the activity of this enzyme in cancer cells. However, in different tumors has been 
reported the modified expression of several nDNA-encoded CI subunits, rather than the occurrence 
of specific mutation since such genetic alterations could be potential transmitted to every daughter 
cell leading to a profound and generalized metabolic alteration 
94, 93
. Recent works reported the 
correlation between poor prognosis in oncological patients with reduced levels of several nDNA-
encoded CI subunits 
95, 96, 20, 97, 98
. In this context, the evaluation of these gene expression levels 
could represent a prognostic marker for tumor outcome at the moment of diagnosis. Conversely, 
others have shown that a reduction of nuclear encoded CI subunit might promote different aspect of 
tumor progression by increasing mitochondrial ROS levels and leading to the activation of the 
Akt/mTOR pathway, which in turn promotes the epithelial-mesenchymal transition (EMT) 
99, 100
 or 
enhancing the metastatic potential of cancer cells 
101
. Although a growing number of works reported 
the existence of a correlation between altered expression of nDNA-encoded CI subunits and their 
influence on different aspect of cancer biology, only few of these studies investigate in deep the 
molecular mechanism behind this relation. 
Conversely, the contribution of mutations in mtDNA genes encoding for CI subunits in different 
aspect of tumor biology, such as tumor progression, metastasis formation, metabolic adaptation and 
therapy resistance, is better characterized since they have been frequently found in several tumors 
94, 93
. The occurrence of somatic mtDNA mutations in cancer is mainly due to the peculiarities of 
this genome. Human mtDNA is a double-stranded circular molecule mostly coding and somatic 
mutations may occur and accumulate since the mitochondrial DNA polymerase (POLG) is error-
prone 
102, 103, 104
. Furthermore, mammalian cells typically contain from hundreds to thousands copies 
of mtDNA that can replicate independently of nDNA 
105
. During cell division, mitochondria are 
randomly distributed to daughter cells indicating that the mutation load can range with time in 
somatic cells 
106
. Given the mtDNA polyploid nature, a condition of homoplasmy is established 
when all copies of this DNA (wild-type or mutant) are all identical to each other, conversely the 
coexistence of different mitochondrial genome in the same cells is a condition known as 
heteroplasmy (Figure 8). Whether a mtDNA mutation occurs, about 70-90% of mtDNA must be 
affected, depends of the mutation type and the energy requirements of the affected cell, in order to 
observe the phenotype (threshold effect) 
105, 102, 103, 107
 (Figure 8). Thus, the phenotypic 
manifestation of mtDNA mutation appears dynamic and variable due to mitotic segregation and 






Figure 8: Threshold effect 
93
. The condition of homoplasmy occurs when all mitochondrial DNA (mtDNA) molecules 
are identical (wild type (WT) or mutant (MUT)), while heteroplasmy implies the coexistence of different mitogenomes. 
Hence, to exert their functional effect mtDNA mutations must be accumulated and surpass a specific mutation threshold 
that depends on the mutation type and the tissue or cell affected.  
 
 
It has been demonstrated that cancer cells are often characterized by the occurrence of 
heteroplasmic mutations, that may depend to the pressure of the tumor microenvironment, since the 
impairment of mitochondrial function may confer a selective advantage to cancer cells 
108, 109
. 
Furthermore, mostly neutral missense mutations are gradually shifted towards homoplasmy over 
time in tumors 
104
. Conversely, severe and disruptive homoplasmic mutations are negatively 
selected by cancer cells underlining the importance of mitochondria in cancer cells 
104
.  
The effect of CI-encoded mtDNA mutations subunits on tumor progression strictly depends on the 
severity of the biochemical defects induced and on the mutant load (Figure 9) 
40, 93
. In this context, 
missense mutations or heteroplasmic disruptive mutations causing mild CI deficiency have been 
related with an increase in mitochondrial ROS production by conferring a growth advantage and 
stimulating aerobic glycolysis through the accumulation of HIF-1α in cancer cells 
110, 111
. Similarly, 
nonsense and missense MT-ND6 mutations and heteroplasmic frameshift m.12417insA/MT-ND5 
mutation, correlated with lower activity of CI, are able to enhance aggressiveness of cancer cells by 
inducing over-production of ROS and promoting the activation of Akt pathway 
112, 108, 113
. However, 
when the mutant load is close to homoplasmy, the same mutations induce a severe CI dysfunction 
that hampers tumorigenic potential promoting apoptosis of tumor cells underlining that the impact 




. In line, our group has demonstrated that homoplasmic mutation m.3571insC/MT-ND1 
impairs CI structure and activity leading to profound metabolic changes, including imbalance of 
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αKG/SA levels and chronic destabilization of HIF-1α hampering tumor growth in vitro and in vivo 
37, 38, 40
. Interestingly, the same mutations when present in heteroplasmic state did not affect tumor 
progression 
37, 38, 39, 40
. This study represents a classical example of oncojanus nature of CI-encoded 
gene mutations that may display a different impact on tumorigenesis as consequence of their 
severity and their effect on the metabolic status of cancer cells.  
Further, some mtDNA mutations in CI genes are involved in metastasis formation and 
chemotherapy resistance, as they may promote oxidative stress, as consequence of reduced CI 
activity, enhancing cancer cells invasiveness and metastatic potential 
114, 115, 116
. However, these data 
are in contrast with others works that highlight the importance of functional or enhanced OXPHOS 
activity to support metastasis formation 
90, 117, 118
. In this light, the contribution of mtDNA mutations 
to foster the metastatic potential need to be better investigate. 
Conversely, growing evidence underline the importance of mitochondrial contribution in tumor 
cells response to chemotherapy treatments. In this regard, we have recently demonstrated the 
involvement of two mtDNA mutations, one of which affect respiratory CI, in cisplatin resistance of 
gynecological origin cancer cells. The occurrence of these genetic alterations reduces proliferative 
and tumorigenic potential, in term of migratory and invasive capacity. At the same time, 
mitochondrial deficiency induces also a damage to cytoskeleton, in particular to filamentous 
tubulin, which is the main target of paclitaxel. It is also demonstrated that such mutations are 
positively selected and became homoplasmic leading cancer cells to acquire a resistant phenotype to 
chemotherapy treatment 
119
. These data are supported by a previously work, in which it is shown the 
insurgence of paclitaxel resistant mass in a patient with ovarian cancer harboring homoplasmic 
disruptive m.10875T>C/MT-ND4 mutation after anti-cancer treatment. Beside the resistance to 
chemotherapy, the occurrence of mtDNA mutation resulted in a more quiescent, non-invasive, and 
low-proliferative neoplasm 
120
. This finding emphasizes once again the oncojanus nature of mtDNA 







Figure 9: The double edge effect of mutations in CI encoding genes on tumorigenesis 
93
. Mild alterations of CI 
activity induce an increase of mitochondrial ROS production leading to the consequent activation of Akt/mTORC1 
pathway which in turn sustain cancer cells proliferation and survival, EMT and HIF-1α stabilization. On the other hand, 
severe CI dysfunction are related to the intracellular accumulation of NADH and αKG, which destabilizes HIF-1α even 
under hypoxic condition preventing the hypoxic adaptation of cancer cells and promoting the arrest of tumor growth.  
 
The potential role of CI inhibitors as novel adjuvant anti-cancer strategy. 
In line with what described above, it is plausible to consider the use of specific inhibitors that 
severely affect CI function as adjuvant treatment for oncological patients. At the same time, we 
have to take in consideration the crucial role played by respiratory CI also in the energy production, 
metabolic pathway and oxidative stress homeostasis in non-cancer cells 
121, 122, 123
. In this regard, the 
difficulty is the development of specific CI inhibitors suitable for the employment as anti-cancer 
agents, without inducing a metabolic catastrophe in non-cancer cells. 
Rotenone, piericidin A and capsaicin are considered as classical CI inhibitors and their 
administration decreases the tumorigenic potential of several cancer cell lines under metabolic 
stress condition 
124, 125, 126
 (Table 1). Nevertheless, rotenone and piericidin A favor an increase in 
ROS production blocking electron transfer from Fe-S clusters to the ubiquinone and therefore their 





Recently, several works have highlighted the emergent role of anti-diabetic biguanides metformin 
and phenformin as potential anti-cancer CI inhibitors. Phenformin is not clinically used since its 
higher risk of lactic acidosis incidence, a possible consequence of mitochondrial CI inhibition 
128
. 
Conversely, metformin is the first line therapy for diabetes mellitus II and epidemiological studies 
revealed that patients treated with this drug have reduced risk to develop cancer and present with a 
better prognosis 
129, 130, 131
. Growing evidences suggested that metformin reduce cancer cell 
proliferation through the specific inhibition of respiratory CI activity 
132, 133, 134
, although the 
molecular mechanism has not been completely elucidated. However, it is demonstrated that 
metformin treatment induces an increase of glucose consumption and lactate production and, at the 
same time, decreases mitochondrial glucose oxidation in cancer cells 
135, 136
. Furthermore, its anti-
proliferative effect results enhanced under glucose starvation 
135, 133
, which is a feature commonly 
shared by most of specific CI inhibitors. In line, novel small molecules (BAY 87-2243 and AG311) 
that humper tumor growth by inhibiting CI activity shown the same ability of metformin to reduce 
cancer cell viability mainly under limited glucose concentration indicating that cancer cells rely 
exclusively on glycolysis to survive after CI inhibition 
137, 138, 139
. A common feature of this new 
class of CI inhibitors is to induce a profound energetic crisis in cancer cells which, in turn, induces 
the phosphorylation and the activation of energetic stress sensor adenosine monophosphate (AMP)-
activated kinase (AMPK). AMPK activation, firstly triggered by CI inhibition, concurs to the anti-
tumorigenic effect through the inhibition of mTORC1 signaling and subsequently promoting the 
cell cycle arrest 
140, 138, 139
. However, this mechanism cannot exclusively explain the anti-
proliferative effect of CI inhibitors since different types of tumors, unable to activate AMPK, are 
still susceptible to these drugs 
140
. Further, CI defective cells activate AMPK signaling probably to 
allow mitochondrial biogenesis and to trigger metabolic adaptation, but this kinase does not concur 
to the arrest of cancer cell proliferation 
40
. Conversely, lack of CI activity caused by disruptive 
mutations or exposure to drugs (metformin, BAY 87-2243 and AG311) destabilizes HIF-1α 






. The inactivity of respiratory CI may cause 
a reduction of intracellular oxygen consumption leading to a condition of intracellular normoxia 
even when the extracellular oxygen tension is low 
141
. Moreover, CI inhibition may promote the 
activation of PHDs, even in hypoxia, as consequence of increasing αKG intracellular levels leading 
to a chronic hydroxylation and degradation of HIF-1α (pseudonormoxia) 
38, 39, 40
. In line, Griss and 
co-workers have demonstrated that metformin treatment greatly reduces the anaplerotic flux of both 
glucose and glutamine into the TCA cycle, leading to a significant reduction of all metabolites of 
the TCA cycle, except αKG 
142
. The increased αKG/SA ratio may thus prevent HIF-1α stabilization 
and consequent activity. Furthermore, unlike the majority of CI inhibitors, metformin 
20 
 
administration is not correlated with an increase of mitochondrial ROS levels 
143, 133, 144
, which are 




During the past years, many efforts have been made to identify small molecules that inhibit HIF-1α 
signaling through different mechanisms, but these inhibitors are often cytotoxic or not specific. The 
link between HIF1α stabilization and mitochondrial function opens to new metabolic-based 
therapeutic approaches for those cancers for which adaptation to hypoxia is a step that must be 
overcome to progress toward malignancy. In this frame, the inhibition of CI activity may be used as 
a strategy to induce a profound energetic and metabolic crisis in cancer cells. Indeed, trough the 
unbalance of NAD
+
/NADH ratio, which in turn affects TCA fluxes and metabolites levels including 
αKG, the lack of CI activity is associated to a constitutive destabilization of HIF-1α 
38, 39, 40
. In this 
way, cancer cells are unable to enhance the glycolytic machinery during hypoxia and display a 



























Table 1: Respiratory CI inhibitors with anti-cancer proprieties 
93
. 
Inhibitor Mechanism of action Cellular model References 
Rotenone Induces cell death under starvation in vitro 
Increases ROS production in vitro 




Piericid A Induces cell death under starvation in vitro 
Increases ROS production in vitro 
Breast, pancreatic and 




Capsaicin Induces cell death under starvation in vitro Breast cancer cells  125 
Metformin Induces cell death under starvation in vitro 
Promotes AMPK phosphorylation 





carcinoma cancer cells 
133, 134,  
140,  145 
Phenformin Induces cell death under starvation in vitro 
Promotes AMPK phosphorylation 
Induces HIF-1α destabilization under 
hypoxic condition 
Colon and breast 
cancer cells and 
xenografts 




Induces cell death under starvation in vitro  
Decreases tumor growth in vivo 
Promotes AMPK phosphorylation 
Induces HIF-1α destabilization under 
hypoxic condition 
Increases intracellular ROS levels 
Lung cancer and 
melanoma cells and 
xenografts  
137, 138 
AG311 Induces cell death under starvation in vitro  
Decreases tumor growth in vivo 
Promotes AMPK phosphorylation 
Induces HIF-1α destabilization under 
hypoxic condition 
Induces mitochondrial superoxide 
production 
Breast cancer cells 
and xenografts  
139, 149 
Fenofibrate Induces cell death in vitro Glioblastoma cells  150 
JCI-20679 Induces cell death in vitro A panel of 39 human 
cancer cell lines 
151 
Celastrol Promotes ROS production and apoptosis in 
vitro 




Kalkitoxin Induces cell death in vitro 
Induces HIF-1α destabilization under 
hypoxic condition 
Neuroblastoma, breast 
and colon cancer cells 153 








Solid tumors are often characterized by hypoxic areas hardly attainable and susceptible to cancer 
therapies. For this reason, these types of cancers result to be very aggressive and associated with 
poor prognosis. Under hypoxic condition, several adaptive changes and metabolic reprogramming 
are promoted and coordinated at transcriptional level by HIF-1. This transcriptional factor is 
considered the master regulator of hypoxic cellular response and plays key roles in development, 
physiology and disease, including cancer. In this context, the idea to develop a pharmacological 
approach able to reduce or inhibit HIF-1 activity in hypoxic cancer regions could represent a 
strategy to prevent an adverse outcome in tumor patients. Despite efforts in the past years, no agents 
directly inhibiting HIF-1 have been approved for treating cancer patients due to safety or limited 
therapeutic efficacy. A few inhibitors interfere directly with its mRNA or protein, the dimerization 
of α and β subunits, or the interaction of HIF with its co-activators, but most of them are indirect 
inhibitors or have other activities. 
HIF-1 is a heterodimeric protein constituted by two different subunits. HIF-1α turn-over and 
stability is strictly regulated by intracellular O2 levels and PHDs activity, while HIF-1β is 
constitutively expressed. Besides intracellular O2 levels, also the abundance of TCA metabolites 
αKG and SA results to be crucial to allosterically regulate PHDs activity. Being one of the products 
of HIF-1α hydroxylation reaction, an increase of SA levels chronically stabilizes HIF-1α by 
inhibiting PHDs. On the contrary, increasing αKG intracellular levels enhance the PHDs affinity for 
O2 and feed their hydroxylation reaction preventing HIF-1α stabilization, even in hypoxia. 
Our research group has previously demonstrated that cancer cells characterized by severe mtDNA 
mutations that impair CI assembly and activity displayed an increase of αKG/SA ratio, likely due to 
the inhibition of αKG dehydrogenase resulting from an increase of NADH intracellular levels. High 
concentrations of αKG promote the activation of PHDs and consequent chronic HIF-1α 
destabilization, even when O2 is available, hampering tumor growth in vitro and in vivo. This 
condition was termed pseudonormoxia. 
Based on these findings, we hypothesized that pseudonormoxia can be induced by unbalancing the 
αKG/SA ratio that mimicking a normoxic condition prevents the hypoxia adaptation. Thus, the 
main goal of this project was to identify novel compounds able to promote PHDs activity triggering 
HIF-1α destabilization and preventing tumor growth and progression. We pursued this objective 
with two different pharmacological approaches. On one hand, we used mitochondrial CI inhibitors 
to indirectly promote the increase of αKG intracellular levels. We attempted to identify new 
molecules able to act as specific CI inhibitors without exerting cytotoxic effect on non-cancer cells 
23 
 
in order to be considered safe and suitable as therapeutic agents. In parallel, we developed a direct 
approach to induce a pseudonormoxic state by increasing αKG intracellular levels using membrane-
permeating ester derivatives of this TCA metabolite.  
In this thesis, we exploited the destabilization of HIF-1α as a potential target for a new possible 
adjuvant cancer therapy. This metabolic-based approach can be envisioned as a strategy for all 
those types of cancer in which hypoxic adaptation and metabolic reprogramming are necessary for 
































TPC-1 (human papillary thyroid cancer cells) and Nthy-ori 3.1 (NTHY 3.1) (non-tumoral thyroid 
follicular epithelial cells) were cultured in RPMI 1640 Medium supplemented with 10% fetal 
bovine serum (FBS), 2 mmol/L L-glutamine, 100 units/mL penicillin, and 100 μg/mL streptomycin. 
HK-2 (non-tumoral renal proximal tubule epithelial cells) and UOK-257 (human renal carcinoma 
cells) were cultured in Dulbecco’s modified Eagle medium (DMEM) High Glucose, supplemented 
with 10% fetal bovine serum (FBS), 2 mmol/L L-glutamine, 100 units/mL penicillin, and 100 





 cell models were generated using NDUFS3-
targeted zinc finger nuclease technology. A clonal selection and genotyping, after the transfection, 
were performed to identify cells with frameshift NDFUS3 mutations. Heterozygous clones were 
first expanded and then a second transfection with NDUFS3 zinc finger pool was performed in 
order to select homozygous frameshift NDUFS3 mutants and homozygous wild-type (WT) 
revertants used as control in all experiments performed in this work. Cells obtained with this 
method were cultured in Dulbecco’s modified Eagle medium (DMEM) High Glucose, 
supplemented with 10% fetal bovine serum (FBS), 2 mmol/L L-glutamine, 100 units/mL penicillin, 
100 μg/mL streptomycin and 50 μg/mL uridine. 
All these cell lines were maintained in an incubator with a humidified atmosphere at 5% CO2 and 
37°C. Experiments in hypoxia were performed using the Invivo2 300 (Baker Ruskinn) incubator, 
set up at 5% CO2, 37°C and 1% O2. Where indicated, cells were incubated with 150 µM of 
desferoxamine (DFO) for 16 hours under normoxic condition and with dimethyl-2-oxoglutarate 
2mM under hypoxic condition. 
Sulforhodamine B (SRB) viability assay 
Cells were seeded in 96-well plates (1x10
3
 cells/well for TPC-1, 2x10
3 
cell/well for NTHY 3.1 and 
UOK-257 cells, 3x10
3 
cell/well for HK-2, 2x10
3 





cells). For additional treatments, cells were incubated 24 hours after seeding with different medium 
for the times and using concentrations indicated in legends of figures.  
At the end of incubations time, cells were fixed to the well with 50% trichloroacetic acid dissolved 
in the grow medium for 1 hour at 4° C, washed 5 times with water and dried at room temperature. 
Cells still attached to the well were incubated for 30 minutes with SRB 0.4% diluted in 1% acetic 
acid at room temperature. SRB is an anionic dye, amino-xanthene, which forms electrostatic 
complexes with the basic protein residues, in weak acid conditions. Subsequently, wells were 
25 
 
washed 4 times with 1% acetic acid to remove excess dye. The dye bound to the cells was finally 
solubilized with 10mM Tris (pH 10.5) and the relative absorbance of SRB was detected using plate 
reader VICTOR
3
 (1420 Multilabel Counter-PerkinElmer, Turku, Finland) at the wavelength of 560 
nm. 
Colony formation assay  
The ability of single cancer cell to grow forming a colony was evaluating by seeding 250 cells/well 




 cells) in a 6-well 
plate in their growth medium. After seeding, cells were incubated at 37° C in a humidified 5% CO2 
atmosphere. To assess the anti-tumorigenic potential of compounds to test, treatments were 
effectuated 24 hours after seeding. Colonies were fixed after 7 or 10 days, for TPC-1 and UOK-257, 
143B respectively, using 50% trichloroacetic acid and incubating cells at 4°C for 1 hour. Then 
colonies were washed 5 times with water, dried, stained with SRB 0.4% diluted in 1% acetic acid 
for 30 minutes at room temperature and destained washing 4 times cells with 1% acetic acid. Image 
were acquired using Gel Logic 1500 Imaging System (Kodak, Ronchester, NY, USA) and the 
number of colonies quantified using ImageJ software. The dye bound to the cells was solubilized 
with 10mM Tris (pH 10.5) and the relative absorbance of SRB was detected using plate reader 
VICTOR
3
 (1420 Multilabel Counter-PerkinElmer, Turku, Finland) at the wavelength of 560 nm. 
Mitochondria isolation 
Enriched mitochondrial fractions were obtained from cells seeded into 10 cm dish and after 24 
hours incubated with KH-compounds for 72 hours using the concentrations shown below. At the 
end of incubation time, cells were trypsinized and mitoplast were obtained resuspending cellular 
pellet (10x10
6
 cells) with cold PBS (154 mM NaCl, 1 mM KH2PO4, 3 mM Na2HPO4) and adding 
digitonin (final concentration 50 µg/ml) for 1 minute. The reaction was blocked by diluting 2,5-fold 
the suspension volume using cold PBS. The digitonin treatment may be repeated until at least 90% 
of cells were permeabilized, as detected at the microscope using Eritrosine B. After that, cells were 
centrifuged at 13000 rpm for 15 minutes at 4°C and the pellet was stored at -80°C. Protein content 
was quantified according to Bradford 
155
. 
Clear Native Page 
Mitoplasts were suspended in mitochondrial buffer (750 mM 6-aminocaproic acid; 50 mM BisTris, 
pH 7.0) and solubilized by adding 2% n-Dodecyl β-D-maltoside (DDM), kept in ice for 10 minutes 
and centrifuged at 13000 rpm for 15 minutes at 4°C. The supernatant was recovered, and 





CN-Sample Buffer (0.1% Red Ponceaux and 50% Glycerol) was added to 50 µg of mitochondrial 
protein sample and loaded onto a native gel constituted by a gradient of polyacrylamide from 4% to 
12%, made with a gradient building machinery and a peristaltic pump (Delta-Pump). The 
electrophoresis was performed at 80V using Anode Buffer (25 mM Imidazole, pH 7) and cathode 
buffer (50 mM Tricine, 7.5 mM Imidazole, 0.02% DDM, 0.05% Sodium Deoxycolate pH 7). 
CI-In Gel Activity 
After electrophoresis, gel was incubated in a solution containing 2 mM Tris-HCl, 0.5% 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 0.02% NADH for 15 minutes at 
room temperature, in the dark. The detection of purple bands on the gel revealed the enzymatic 
function of CI in a single complex or in supercomplexes and the colorimetric reaction was due to 
reduction of MTT to tetrazolium salts by NADH oxidation through CI. Image were acquired using 
Gel Logic 1500 Imaging System (Kodak, Ronchester, NY, USA). 
Total lysates 
Cells were seeded in 6-well plate and after 24 hours were incubated with 200µM of αKGlogues for 
different time points. At the endo of incubation time, cells were trypsinized and the pellet was 
washed once with PBS and centrifugated at 13000 rpm for 1 minute at 4°C. Then, the pellet was 
resuspended in RIPA buffer (50mM TrisHCl pH7.4, 150mM NaCl, 1% SDS, 1% Triton, 1mM 
EDTA pH7.6) supplemented with protein and phosphatase inhibitors and incubated for 15 minutes 
in ice. The lysate was frozen and thawed twice and centrifugate at 13000 rpm for 15 minutes at 4°C. 
The supernatant was recovered, and the protein content quantified using Bradford’s method 
155
. 
SDS-PAGE and Western Blot 
Total lysates, obtained as described above, were added with Laemmli sample buffer 5X (62,8mM 
Tris pH 6.8, 12,5% glycerol, 2% SDS, 0,7M 2- mercaptoethanol, 0,1% bromophenol blue) and 
boiled for 5 minutes to induce complete protein denaturation. Denaturing SDS-PAGE 
Electrophoresis was carried out at 100V at room temperature in Sodium Dodecyl Sulphate (SDS) 
running buffer (250mM Tris, 2M glycine, 40mM SDS). At the end of the run, proteins were 
transferred onto a nitrocellulose membrane 0.45mm in full-wet system in Western Transfer Buffer 
(25mM Tris pH 8,3, 93mM glycine, 20% methanol) at 100V for 1 hour at room temperature using 
Bio-Rad Mini Trans-Blot Cell system. After, the membrane was incubated in powdered milk solved 
in TBS 1X-Tween 0.05% (25mM Tris-HCl pH 7.5, 137mM NaCl, 0,05% Tween) for 1 hour at 
room temperature and incubated with primary antibodies using following dilutions/conditions: anti-
HIF1a (GeneTex GTX127309) 1:2000, 2 hours at room temperature; anti-β-Actin (Sigma-Aldrich 
cat# SAB5500001) 1:5000, 2 hours at room temperature; anti-NDUFS3 (Abcam cat# ab110246) 
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1:1000 2 hours at room temperature; anti-NDUFA9 (InVitrogen cat# ab14713) 1:1000 2 hours at 
room temperature; anti-NDUFB8 (Abcam cat# ab110242) 1:1000 2 hours at room temperature; 
anti-SDHA (InVitrogen cat# ab459200) 1:10000, 2 hours at room temperature; anti-VDAC (Abcam 
cat# ab154856) 1:1000, 2 hours at room temperature. 
Membranes were washed 3 times with TBS 1X-Tween 0.05% and incubated with the proper 
secondary antibody (Jackson ImmunoResearch Laboratories Anti-Mouse cat# 115035003 and Anti-
Rabbit cat# 211032171) diluted 1:5000/1 hour at room temperature. After further 3 wash in TBS 
1X-Tween 0.05% and chemiluminescence was obtained by ECL. Images were acquired using Gel 
Logic 1500 Imaging System (Kodak, Ronchester, NY, USA). The densitometric analysis was 
performed using ImageJ software. 
KH-compounds 
KH-compounds were produced by Khondrion, a Dutch pharmaceutical company located in 
Nijmegen, The Netherlands. Cells were treated with these molecules for different time points using 
concentrations indicated by Khondrion and reported in the table below (Table 2). 
 
Compound Structure Concentration 
KH407 undisclosed 300µM 
KH412 undisclosed 300µM 
KH426 undisclosed 300µM 
KH474 undisclosed 300µM 
KH0B undisclosed 10µM 












Table 2: In the panel were reported the name of KH- compounds and relative concentration used for all experiments 




To increase αKG permeability across the plasma membrane, several carriers, characterized by 
different hydrophobic indices, were conjugated to αKG through an ester bound. In viability and 
colony formation assays, cells were treated for different time points with 2µM, 20µM and 200µM 

































CI inhibitors: an indirect approach to induce a pseudonormoxic state in cancer 
cells. 
During these years, a growing number of papers have highlighted the crucial role of respiratory CI 
in cancer. Functional defects caused by mutations or altered expression levels of its subunits lead to 
opposite effect in the modulation of tumorigenic potential 
93
. Our research group has demonstrated 
that CI-deficient cells are characterized by profound metabolic alterations, including the imbalance 
of αKG/SA ratio, which are related with the cancer cells growth arrest both in vitro and in vivo. We 
reported that increased αKG intracellular levels allosterically promote PHDs activity boosting the 
continuous hydroxylation and degradation of HIF-1α and preventing hypoxic adaptation 
37, 38, 39, 40
. 
Therefore, the use of specific CI inhibitors may be adopted as a pharmacological strategy to induce 
a pseudonormoxic state in HIF-1 dependent cancer cells. In this context, several compounds have 
been recently identified as CI inhibitors with a potential anti-proliferative activity on cancer cells 
and, interestingly, most of them shared the ability to target the same pathways identified through the 
ablation of CI by genetic studies, including adaptation to hypoxia. These findings support our 
hypothesis that the inhibition of CI activity is disadvantageous for tumor progression and opens the 
door to new possible therapeutic approaches for solid tumors, as mitochondrial function and 
adaptation to hypoxia are pivotal for tumor progression. 
 
The specific anti-cancer effect of KH-compounds in thyroid cells does not depend on 
respiratory CI inhibition. 
A panel of six compounds (KH) produced by Khondrion company were screened in our laboratory 
in order to evaluate their potential inhibitor effect on respiratory CI activity. First, we assessed 
whether treatment with these molecules may prevent cancer cell growth in vitro, without exerting a 
cytotoxic effect on non-cancer cells. To this purpose, thyroid-derived cells NTHY 3.1 and TPC-1 
were treated for 24, 48 and 72 hours with these compounds and cell proliferation was evaluated. 
Based on previous screening performed by Khondrion, compounds KH407, KH412, KH426 and 
KH474 were tested using 300µM of concentration, while KH0B and KH0C were employed at lower 
concentration (10µM). 
The treatment with KH407 reduced NTHY 3.1 cell proliferation ~3.5-fold compared to 
corresponding untreated cells after 72 hours (Figure 10A, 10G). Another compound that had shown 
to large influence NTHY 3.1 cell viability was KH0C. In fact, a cytostatic effect was observed 
treating cells with this compound (Figure 10F, 10G). Conversely, a slight but significant decrease of 
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cell growth was observed only after 72 hours incubating NTHY 3.1 cells with KH412 and KH0B 
(Figure 10B, 10E). The compounds KH474 and KH426 did not altered cell viability compared to 
untreated cells (Figure 10C, 10D). All KH-compounds tested exerted almost the same effect shown 
in thyroid normal cells in cancer cells counterpart (Figure 11). KH407 and KH0C were the most 
effecting compounds in reducing TPC-1 cell viability promoting a cytostatic effect (Figure 11A, 
11F, 11G), while KH-412 and KH0B significant decreased cell viability at 72h (Figure 11B, 11E, 
11G). Furthermore, differently from NTHY 3.1 cells, KH474 induced a reduction of TPC-1 
viability after 72 hours in a significant manner, while did not affect NTHY 3.1 cell proliferation 
(Figure 10G, 11G).  
As already said, one of the main goals of this PhD project was to identify new CI inhibitors that 
displayed an anti-tumorigenic potential in vitro but, at the same time, could be considered safe for 
their effect on non-cancer cells. For this reason, KH407 and KH0C were excluded from subsequent 
studies since they had shown a more severe impact to reduce NTHY 3.1 cell proliferation compared 
to other molecules tested, particularly after 72 hours of treatment (Figure 10G). The compound 
KH426 did not reduce TPC-1 cell proliferation; therefore, independently to its effect on NTHY 3.1 
cell viability, was also not considered for further studies (Figure 10D, 10G, 11D, 11G). Conversely, 
TPC-1 cell growth was reduced ~2.5-fold after 72 hours of treatment with KH412 and KH0B, while 
the same molecules were able to decrease NTHY 3.1 viability ~1.5-fold always after 72 hours 
(Figure 10G, 11G). Therefore, these compounds were the most promising for further investigations. 
Similarly, we decided to proceed our study using also KH474 compound since it reduced 










Figure 10: KH407 and KH0C induce the arrest of NTHY 3.1 cells proliferation, while other KH-compounds 
have a mild effect to reduce their growth. (A-F) NTHY 3.1 cells were incubated for 24, 48 and 72 hours with 
KH407, KH412, KH474 and KH426 (300µM) and KH0B and KH0C (10µM). Cell viability was determined using 
SRB assay. Data (mean ± SEM) are expressed in percentage considering as 100% the cell viability at T0 (n=3). NT= 
Not-Treated cells. (G) Bar graph represented NTHY 3.1 cell viability after 72 hours of treatment with KH-
compounds. Data (mean ± SEM) are expressed in percentage considering as 100% the cell viability at T0. Asterisks 










Figure 11: KH412, KH-474 and KH0B reduce TPC-1 cell growth without inducing out-side effects on 
NTHY3.1 cell viability. (A-F) TPC-1 cells were incubated for 24, 48 and 72 hours with KH407, KH412, KH474 
and KH426 (300µM) and KH0B and KH0C (10µM). Cell viability was determined using SRB assay. Data (mean ± 
SEM) are expressed in percentage considering as 100% the cell viability at T0 (n=3). NT= Not-Treated cells. (G) 
Bar graph represented TPC-1 cell viability after 72 hours of treatment with KH-compounds. Data (mean ± SEM) are 
expressed in percentage considering as 100% the cell viability at T0. Asterisks represented * p-value ≤ 0.05, ** p-
value ≤ 0.01 and *** p-value ≤ 0.001 relative to not-treated cells using Student’s T-test. 
33 
 
To investigate the anti-tumorigenic potential of these three molecules, we performed a colony 
formation assay treating TPC-1 cells with KH-compounds previously selected. The ability to form 
colonies from a single cell is one of the peculiarities of cancer cells. This in vitro test allowed us to 
evaluate the ability of KH412, KH474 and KH0B compounds to inhibit cancer cell growth. In this 
context, the reduction in the number of colonies can derive either from the block of proliferation or 
from the induction of cell death. All molecules tested were able to reduce the number of colonies 
formed by TPC-1, with KH412 and KH0B being the more effective (Figure 12A, 12B). Thus, all 
three molecules may be considered as good candidates for more detailed studies of anti-tumorigenic 








To clarify whether these molecules specifically act on respiratory CI, its enzymatic function was 
determined by hrCNE-PAGE followed by Complex I in-gel activity (CI-IGA) and the expression 
levels of different CI subunits were evaluated by SDS-PAGE in isolated mitochondria. NTHY 3.1 
and TPC-1 cells were incubated for 72 hours with KH412, KH474 and KH0B compounds showing 
that none of these was able to decrease CI activity compared to not-treated cells in both cancer and 
non-cancer models (Figure 13). However, though CI assembly and function did not appear to be 
altered, KH412, KH474 and KH0B treatment reduced the protein levels of several CI subunits 
(NDUFA9, NDUFS3 and NDUFB8) in TPC-1 cells. Further, it was also observed a decrease of 
VDAC protein levels, normally expressed at steady-state levels and considered as mitochondrial 
Figure 12: The treatment with KH412, KH474 and KH407 decreases the clonogenic capacity of TPC-1 cells. 
(A) Colony formation assay performed in six-well plates. TPC-1 cells were treated for one week with 300µM of 
KH412 and KH474 and with 10µM of KH0B. NT= Not-Treated cells.  (B) Number of colonies were counted using 
ImageJ software. Data (mean ± SEM) n=3. Asterisks represented ** p-value ≤ 0.01 and *** p-value ≤ 0.001 relative 




loading control (Figure 13).  In this context, the most effective compound was KH474, although it 
promoted a lower effect to decrease the tumorigenic potential in vitro compared to KH412 and 
KH0B. Moreover, in contrast with the latter compounds, TPC-1 treatment with KH474 induced also 
a lower expression of SDHA protein, the major catalytic subunit of succinate-ubiquinone 
oxidoreductase (Figure 13). This overall decrease in mitochondrial protein levels may indicate that 
this compound induced an extensive damage on mitochondria, probably affecting their biogenesis 


















In NTHY 3.1 cells, none of the analyzed compounds was able to decrease respiratory CI activity 
(Figure 13). On the other hand, CI subunits appeared to be more express after treatment with KH-
compounds compared to untreated cells and, in contrast to what observed in TPC-1 cells, VDAC 
protein levels were not altered (Figure 13). It seems that the capacity of KH412, KH474 and KH0B 
to potentially affect mitochondrial biogenesis or inducing massive mitophagy, as supposed before, 
is a cell specific response of TPC-1 cells. It may be also possible that the effect promoted by these 
compounds on mitochondria is cancer specific, but to support this hypothesis further studies are 
necessary using different cell models. Lastly, KH474 showed the same effect observed in TPC-1 
cells reducing SDHA protein levels also in NTHY 3.1 cells (Figure 13). 
Figure 13: KH-compounds trigger a lower mitochondrial protein expression, included several CI subunits, in 
TPC-1 cells without affecting CI activity. CI-IGA and western blot analysis of different mitochondrial protein in 
NTHY 3.1 and TPC-1 isolated mitochondria after treatment for 72 hours with 300µM of KH412 and KH474 and 
with 10µM of KH0B. VDAC was used as loading control. 
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Overall, these data supported the observation that KH412, KH474 and KH0B may be considered as 
interesting molecules displaying a specific anti-tumorigenic potential in thyroid cancer models. The 
reduction of several mitochondrial protein levels promoted by these molecules in TPC-1 cells 
indicate the existence of a link between their anti-tumorigenic activity and the importance of 
mitochondria in cancer. Indeed, mitochondria play a central and multi-functional role in malignant 
tumor progression and targeting mitochondria may provide a therapeutic opportunity. Despite these 
intriguing observations, none of these compounds was able to inhibit or reduce respiratory CI 
activity. For that reason, we decided to move away from this research line in order to focus our 
attention on other compounds capable to induce a pseudonormoxic state in HIF-1-dependent tumors 
by specifically inhibiting respiratory CI activity. 
The anti-tumorigenic potential of metformin mainly derives from CI-independent 
mechanisms. 
Metformin has been widely used for many years for treatment of type II diabetes and several 
epidemiological studies highlighted its beneficial effect in oncologic patients, in terms of reduced 
risk to develop disease and better prognosis 
129, 130, 131
. Recently, the anti-tumorigenic activity of 
metformin was associated with its potential activity as respiratory CI inhibitor, although the 
mechanisms through which it prevents tumor progression are not fully understood and comprises 
CI-independent activities. To elucidate this point, we exploited a unique cell model generated in our 
laboratory in which we specifically ablated NDUFS3 gene in osteosarcoma 143B cells via gene 
editing 
156
. NDUFS3 is core nDNA-encoded subunits located in the site of CI responsible for the 
electron transfer to ubiquinone (Q-module). The knock-out of this subunit abolished CI assembly 
and activity almost completely 
156
 and isogenic NDUFS3
+/+
 cells were used as controls. Hence, cells 
lacking fully assembled respiratory CI missed the major molecular target of metformin and 
consequently should be less susceptible to the treatment. 
First, we evaluated the effect of 10mM and 20mM metformin on cell proliferation, treating 143B 
NDUFS3
+/+
 (used as controls) and 143B NDUFS3
-/- 
cells for multiple time points. A clear dose-
dependent effect of metformin in reducing cell growth after 48 and 72 hours was observed in 143B 
NDUFS3
+/+
 cells (Figure 14A, 14C). Conversely, 143B NDUFS3
-/-
 viability was significantly 
decreased after 48 and 72 hours of treatment with 20mM of metformin compared to corresponding 









These data suggested that it was possible to observe a decrease of cell proliferation mainly 
dependent on metformin CI inhibitory effect using 10mM of concentration, whereas not specific 
effects prevailed when cells were treated with higher doses of drug. Normalizing data on not-treated 









 cells was reduced about 
40% and 20% respectively compared to not-treated cells after treatment with 10mM of metformin 
for 72 hours (Figure 15A). Cell growth was reduced by 80% in 143B NDUFS3
+/+
 cells and almost 
60% in 143B NDUFS3
-/- 
cells after 72 hours of treatment with 20mM metformin (Figure 15B). 
These data suggested that at high concentration, metformin exerted a greater effect in reducing cell 
proliferation in vitro independently from the presence of functional respiratory CI and that this drug 
may impact other unidentified molecular targets at least in osteosarcoma background. Furthermore, 
the specificity towards 143B NDUFS3
+/+
 cells, rather than NDUFS3
-/-
 cells, was about 20% with 
Figure 14: Metformin reduces osteosarcoma cells viability in a specific CI-dependent manner using 10mM of 
concentration. (A, B) 143B NDUFS3
+/+
 and 143B NDUFS3
-/-
 cells were incubated for 24, 48 and 72 hours with 
10mM of metformin. (C, D) 143B NDUFS3
+/+
 and 143B NDUFS3
-/- 
cells were incubated for 24, 48 and 72 hours 
with 20mM of metformin. Cell viability was determined using SRB assay. Data (mean ± SEM) are expressed in 
percentage considering as 100% the cell viability at T0 (n=5). NT= Not-Treated cells. Asterisks represented * p-
value ≤ 0.05, ** p-value ≤ 0.01 and *** p-value ≤ 0.001 relative to not-treated cells using Student’s T-test. 
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both metformin concentrations tested suggesting that the anti-proliferative effect was not mostly 















 cells were incubated for 10 days with 10mM of 
metformin in order to evaluate their clonogenic capacity under inhibition of CI activity. A reduction 
of colonies size was observed after treatment with metformin, but without significant changes in 





models (Figure 16A, 16B, 16C), confirming that metformin did not induce cells death, but 





Figure 15: Non-specific effect of metformin mainly determines the decrease of osteosarcoma cell 




 cells were incubated for 24, 48 and 72 hours with 10mM of 




cells were incubated for 24, 48 and 72 hours with 20mM of 
metformin. Cell viability was determined using SRB assay. Data (mean ± SEM) are expressed in percentage 










There are evidences in literature regarding the role of metformin to reduce the hypoxic stabilization 
of HIF-1α protein and HIF-dependent target genes through the inhibition of respiratory CI 
133
. This 
is consistent with the inhibitory effect exerted on HIF-1α by a large amount of canonical and novel 
CI inhibitors 
93
. In line with these findings, although the inhibitory effect on CI did not seem to be 
the main molecular mechanism through which metformin promoted its anti-tumorigenic potential in 
our osteosarcoma models, we investigated the impact of metformin treatment on HIF-1α protein 
levels under hypoxic condition. 143B NDUFS3
+/+
 cells were pre-incubated in hypoxia for 30 
minutes (T0) in order to induce HIF-1α stabilization and then cells were treated with metformin for 
2, 6, 16 and 24 hours. Western blot analysis showed that drug treatment decreased HIF-1α protein 
levels compared to non-treated at every time points tested (Figure 17A, 17B). These data allowed us 
Figure 16: Metformin treatment induces cell growth arrest independently from CI-activity in osteosarcoma 




 cells were treated 
for ten days with 10mM of metformin. NT=Not-Treated cells. (B) Number of colonies were counted using ImageJ 
software. (C) The absorbance (abs) of SRB is a measure of the area occupied by cell colonies representing an 
indirect index of colonies size. Data (mean ± SEM), n=3. Asterisks represented * p-value ≤ 0.05 using Student’s T-




to speculate that metformin might induce a pseudonormoxic state in hypoxic cells through its 





















In order to generalize our observations and to determine whether metformin could exert a specific 
anti-proliferative effect in cancer cells while being not toxic, cancer and non-cancer CI-competent 
cell models were treated with metformin and cell proliferation, colony formation and HIF-1α 
stability determined. Cell viability assay was performed in both normoxic (21% O2) and hypoxic 
(1% O2) conditions in thyroid and renal cell models in absence and presence of 10mM of metformin 
for 24, 48 and 72 hours. Under normoxic condition, metformin treatment induced a slight reduction 
of NTHY 3.1 and TPC-1 cell proliferation respectively after 72 and 48 hours of treatment compared 
to corresponding not-treated cells (Figure 18A, 18B). On the contrary, a specific anti-cancer cell 
proliferation effect was observed under hypoxic condition. In fact, at low oxygen levels, metformin 
induced only a mild effect on NTHY 3.1 cell proliferation after 72 hours of treatment, whereas 
Figure 17: Metformin reduces HIF-1α protein levels in 143B NDUFS3
+/+
 cells under hypoxic condition. (A) 
Western blot analysis of HIF-1α protein levels after treatment with 10mM of metformin in 143B NDUFS3
+/+
 cells 
for 2, 6, 16 and 24 hours under hypoxic condition (1% O2). β-Actin was used as loading control. (B) Densitometric 




TPC-1 cell growth was largely inhibited already after 48 hours and was reduced 3-fold compared to 
not-treated cells after 72 hours (Figure 18C, 18D). Hence, metformin differently affected TPC-1 
cell proliferation depending on intracellular oxygen levels. The specific anti-cancer effect observed 
in hypoxia could be explained by a higher capacity of TPC-1 cells to stabilize HIF-1α compared to 
NTHY 3.1 cells (Figure 25A, 25B), which in turn might explain the greater impact of metformin to 










Figure 18: Metformin triggers a specific anti-proliferative effect depending on cellular O2 levels in thyroid 
cells. (A, B) NTHY 3.1 and TPC-1 cells were respectively incubated for 24, 48 and 72 hours with 10mM of 
metformin under normoxic condition (21% O2). (C, D) NTHY 3.1 and TPC-1 cells were incubated for 24, 48 and 72 
hours with 10mM of metformin under hypoxic condition (1% O2). Cell viability was determined using SRB assay. 
Data (mean ± SEM) are expressed in percentage considering as 100% the cell viability at T0 (n=3). NT= not-treated 
cells. Asterisks represented * p-value ≤ 0.05, ** p-value ≤ 0.01 and *** p-value ≤ 0.001 relative to non-treated cells 
using Student’s T-test. 
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Furthermore, the TPC-1 clonogenic capacity was completely abolished after metformin treatment 
for one week (Figure 19A, 19B). In parallel, the western blot showed that also HIF-1α protein levels 
were reduced compared to corresponding not-treating cells after metformin administration under 
hypoxic condition for 2, 6, 16 and 24 hours (Figure 19C). Overall, these data suggested that the 
anti-proliferative effect induced in vitro by this drug may be related to its ability to reduce HIF-1α 
stability in hypoxia. Supported by previous data obtained using osteosarcoma CI-competent cells, it 
is possible to assume that metformin is able to hamper thyroid tumor growth by promoting a 










Figure 19: Metformin completely abolishes TPC-1 clonogenic capacity and also reduces HIF-1α protein levels 
under hypoxic condition. (A) Colony formation assay performed in six-well plates. TPC-1 cells were treated for 
seven days with 10mM of metformin. NT=Not-Treated cells. (B) Number of colonies were counted using ImageJ 
software. Data (mean ± SEM), n=3. Asterisks represented *** p-value ≤ 0.001 using Student’s T-test comparing 
not-treated cells to metformin treated cells. (C) Western blot analysis of HIF-1α protein levels after treatment with 
10mM of metformin in TPC-1 cells for 2, 6, 16 and 24 hours under hypoxic condition (1% O2). β-Actin was used as 
loading control. DFO was used as positive control for normoxic HIF-1α induction. 
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In both renal cell models, metformin did not show any effect on cell proliferation compared to not-
treated cells under normoxic or hypoxic conditions (Figure 20A, 20B, 20C, 20D), suggesting that 
the molecular mechanisms through which metformin induces its anti-tumorigenic potential might 
depend on cell type. However, it is important to consider that UOK-257 cells are characterized by 
the presence of mutant copy of the folliculin (FLCN) gene 
157
. The occurrence of these genomic 
alteration is related to a higher dependency of UOK-257 on glucose metabolism caused by 
increased HIF-1α activity and by altered metabolism. This dependence on a single fuel for 
metabolic production of ATP is known as a loss of “metabolic flexibility”, which is a common 
feature of insulin resistance 
158
. These findings may explain the lack of metformin efficacy to 






Figure 20: Metformin does not affect cancer cell proliferation in renal cells models. (A, B) HK-2 and UOK-257 
cells were respectively incubated for 24, 48 and 72 hours with 10mM of metformin under normoxic condition (21% 
O2). (C, D) HK-2 and UOK-257 cells were respectively incubated for 24, 48 and 72 hours with 10mM of metformin 
under hypoxic condition (1% O2). Cell viability was determined using SRB assay. Data (mean ± SEM) are 
expressed in percentage considering as 100% the cell viability at T0 (n=3). NT= non-treated cells. Asterisks 




Interestingly, more long-term exposure to metformin significantly reduced UOK-257 clonogenic 
capacity in vitro suggesting that this drug might require a specific time to be effective in preventing 
renal cancer cell growth (Figure 21A, 21B). Indeed, cells were treated for ten days to perform the 
colony assay formation. In line, metformin treatment reduced HIF-1α protein levels under hypoxic 
condition 3-fold compared not-treated cells after 24 hours, while just a slight decreased was 











Figure 21: The anti-tumorigenic potential of metformin is dependent on exposure time and on cancer cells 
type. (A) Colony formation assay performed in six-well plates. UOK-257 cells were treated for seven days with 
10mM of metformin. NT=Not-Treated cells. (B) Number of colonies were counted using ImageJ software. Data 
(mean ± SEM), n=3. Asterisks represented *** p-value ≤ 0.001 using Student’s T-test comparing not-treated cells to 
metformin treated cells. (C) Western blot analysis of HIF-1α protein levels after treatment with 10mM of metformin 
in UOK-257 cells for 2, 6, 16 and 24 hours under hypoxic condition (1% O2). β-Actin was used as loading control. 
DFO was used as positive control for normoxic HIF-1α induction. (D) Densitometric evaluation of HIF-1α protein 




In conclusion, our data suggest that metformin reduced tumor growth in vitro, although its anti-
proliferative effect seemed to be mainly due to systemic effect rather than the specific inhibition of 
mitochondrial CI activity, at least in our osteosarcoma CI-deficient and CI-competent cells. The 
anti-tumorigenic activity of metformin also depended on the tissue origin of cancer cells and on the 
time exposure to the treatment. Interestingly, the treatment did not alter non-cancer cell viability in 
both thyroid and renal cell models. Furthermore, we demonstrated that this antidiabetic drug 
reduced HIF-1α protein levels under hypoxic condition in different cancer cell lines. This result is 
consistent with the possibility that metformin reduces HIF-1α stability through the inhibition of CI 
since several inhibitors of this mitochondrial enzyme share the ability to target the same pathways, 
including cancer cell adaptation to hypoxia 
93
. In this context, metformin may therefore be a 




















αKGlogues as a metabolic tool to induce a pseudonormoxic state in hypoxic cancer 
cells. 
The second approach to induce a condition of pseudonormoxia was the direct increase of 
intracellular αKG levels. However, αKG is a hydrophilic metabolite and does not permeate the 
plasma membrane. Hence, in collaboration with Prof. Locatelli’s group from Department of 
Pharmacy and Biotechnology (FaBiT) of University of Bologna, seven αKGlogues were designed 
and synthetized with the aim to boost αKG membrane permeability, to increase its intracellular 
levels and to promote PHDs activity under hypoxic condition. The experimental plan was to bound 
carriers characterized by different hydrophobic indices to αKG, in order to allow it to cross the 
plasma membrane. Once αKGlogues entered into the cell, the ester bound that conjugated the αKG 
to the hydrophobic carrier should be recognized from cytosolic non-specific diesterases leading to 
the αKG intracellular accumulation. 
Isoprenoid carriers contribute to reduce cancer cells proliferation per se.  
The treatment with αKGlogues, besides αKG, may also induce the raised intracellular amount of 
hydrophobic carriers. Most of the carriers selected were phenyl, alkyl or methyl substituents, which 
are not supposed to show any biological function when released into the cytosol. However, we also 
tested three hydrophobic carriers (carriers A, B and C) that are natural isoprenoid molecules, some 
of which are already known to have an anti-cancer activity. For this reason, these three carriers were 
screened for their possible synergic/antagonist effect with αKG and for their cytotoxicity using the 
already described thyroid and renal cell lines. Cell viability assay was performed at multiple time 
points testing different concentrations of these compounds. The cell viability of NTHY 3.1 was 
reduced already after 24 hours of treatment with all concentration tested of carrier A (Figure 22A). 
Furthermore, it was observed a cytostatic effect after 72 hours incubating cells with 150µM and 
200µM of this molecule. Under these conditions, NTHY 3.1 cell growth decreased ~4-fold 
compared to corresponding untreated cells, but without going under the number of cells seeded 
before the treatment with carrier A (time zero, T0), considered as the 100%, indicating an arrest of 
cell proliferation (Figure 22B). Similarly, viability of TPC-1 was reduced in a dose-dependent 
manner, except with 2µM of carrier A that did not alter thyroid cancer cell viability at any time 
points (Figure 22C). In particular, carrier A exerted a cytostatic effect also in TPC-1 using 100µM, 
150µM and 200µM of concentration after 72 hours (Figure 22D). These data suggest that this 
compound could significantly dampen thyroid cell growth, especially at high concentrations (above 
100µM) without showing a cytotoxic effect. 
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The capacity of carrier A to alter renal cells proliferation was weaker compared the effect shown on 
thyroid cells. In fact, HK-2 cell viability was significantly reduced after 24, 48 and 72 hours of 
treatment with 200µM of carrier A and after 72 hours with 100µM, 150µM (Figure 22E). 
Conversely, UOK-257 cell viability was not affected after the incubation with this compound at any 
concentration tested (Figure 22F). 
The second hydrophobic carrier screened for its possible synergistic/antagonist effect with αKG and 
its cytotoxicity was carrier B. All concentration tested were able to reduce significantly NTHY 3.1 
cell proliferation after 24, 48 and 72 hours of treatment (Figure 23A). As observed with compound 
A, also the carrier B exerted a cytostatic effect inducing the arrest of NTHY 3.1 proliferation after 
72 hours of incubation with 150µM and 200µM of concentration (Figure 23B). Conversely, a dose-
dependent decrease of TPC-1 cell growth was observed after treatment with carrier B, although 
without inducing a cytostatic effect as in thyroid non-cancer cells (Figure 23C, 23D). In renal cell 
models, the treatment with carrier B induced a decrease of HK-2 cell growth that was significant 
using 50µM, 100µM, 150µM and 200µM of concentration for 72 hours (Figure 23E). In UOK-257, 
there were not observed alteration on cell viability incubating cells with different concentrations of 
this compound for multiple time points (Figure 23F). Thus, the effect showed by both carrier A and 
B was almost the same in renal cells. 
The last compound screened was carrier C, which induced a dose-dependent decrease of NTHY 3.1 
cell proliferation using 100µM, 150µM and 200µM of concentration (Figure 24A). Differently from 
other two isoprenoid compounds, the treatment with 150µM and 200µM of carrier C caused a 
cytotoxic effect on NTHY 3.1 cell growth after 72 hours (Figure 24B). In this case it was not induce 
a block of cell proliferation since the NTHY 3.1 cell visibility was reduced by 30% and 85% 
compared the amount of cells seeded before the incubation for 72 hours (T0) with 150µM and 
200µM of carrier C, respectively (Figure 24B). In TPC-1 cells, a significant decrease of cell 
proliferation was observed after treatment with all concentration tested, whereas a cytostatic effect 
was trigged incubating cells with 200µM of carrier C for 72 hours (Figure 24C, 24D). On the other 











Figure 22: Carrier A induces a cytostatic effect on cell proliferation in both thyroid cancer and non-cancer 
cells at higher concentrations tested, while it does not alter the proliferative capacity of renal cancer cells.  
(A, C) NTHY 3.1 and TPC-1 cells were grown in increasing dose of carrier A (2µM, 20µM, 50µM, 100µM, 150µM 
and 200µM) for 24, 48 and 72 hours. (B, D) Carrier A effect on NTHY 3.1 and TPC-1 cell viability after 72 hours 
of treatment at different concentrations. (E, F) HK-2 and UOK-257 cells were grown in increasing dose of Carrier 
A (2µM, 20µM, 50µM, 100µM, 150µM and 200µM) for 24, 48 and 72 hours. Cell viability was determined using 
SRB assay. Data (mean ± SEM) are expressed in percentage considering as 100% the T0 (time zero) (n=3). 







Figure 23: Carrier B significantly decreases thyroid cell growth, but it does not display an anti-proliferative 
effect on renal cancer cell growth in vitro. (A, C) NTHY 3.1 and TPC-1 cells were grown in increasing dose of 
Carrier B (2µM, 20µM, 50µM, 100µM, 150µM and 200µM) for 24, 48 and 72 hours. (B, D) Carrier B effect on 
NTHY 3.1 and TPC-1 cell viability after 72 hours of treatment at different concentrations. (E, F) HK-2 and UOK-
257 cells were grown in increasing dose of Carrier B (2µM, 20µM, 50µM, 100µM, 150µM and 200µM) for 24, 48 
and 72 hours. Cell viability was determined using SRB assay. Data (mean ± SEM) are expressed in percentage 
considering as 100% the cell viability at T0 (n=3). Asterisks represented * p-value ≤ 0.05, ** p-value ≤ 0.01 and *** 






 Figure 24: A cytotoxic effect is exerted by carrier C treatment in thyroid non-cancer cells at higher 
concentration tested. The same treatment does not induce an alteration of renal cell proliferation. (A, C) 
NTHY 3.1 and TPC-1 cells were grown in increasing dose of carrier C (2µM, 20µM, 50µM, 100µM, 150µM and 
200µM) for 24, 48 and 72 hours. (B, D) Carrier C effect on NTHY 3.1 and TPC-1 cell viability after 72 hours of 
treatment at different concentrations (E, F) HK-2 and UOK-257 cells were grown in increasing dose of Carrier C 
(2µM, 20µM, 50µM, 100µM, 150µM and 200µM) for 24, 48 and 72 hours. Cell viability was determined using 
SRB assay. Data (mean ± SEM) are expressed in percentage considering as 100% the cell viability at T0 (n=3). 





Overall, these data suggested that carrier A and B may have a synergistic effect with αKG, when 
conjugated to this metabolite to form the corresponding αKGlogue, to reduce thyroid cancer cells 
proliferation in vitro, specially using 100µM, 150µM and 200µM of concentration. However, it is 
important to consider that the same compounds induced a block of NTHY 3.1 cell proliferation 
treating these cells with 150µM and 200µM of concentration for 72 hours. Concerning the carrier 
C, we decided to exclude this hydrophobic carrier since high concentrations (150µM and 200µM) 
were able to kill normal thyroid cells. 
The effect showed by all isoprenoid carriers tested was completely different in renal cells compared 
to thyroid models. None of them altered UOK-257 cell proliferation indicating that potential effect 
of corresponding αKGlogues to reduce renal cancer cell viability in vitro could be ascribed 
exclusively to αKG. Furthermore, carrier A and B promoted a slight but significant decrease of HK-
2 proliferation after 72 of treatment with 100µM, 150µM and 200µM of concentration. Therefore, 
αKG may potentially exerted a synergic effect with these carriers to humper renal normal cells 
growth that we will take into account using the corresponding αKGlogues. Instead, carrier C did not 
alter neither renal cancer nor non-cancer cell proliferation suggesting that, when conjugated to 
αKG, should not have a synergic effect to reduce the tumorigenic potential of cancer cells. 
αKGlogues destabilize HIF-1α protein levels under hypoxic condition. 
In order to determine the effect of αKGlogues on HIF-1α stabilization under hypoxic conditions 
(1% O2), we treated thyroid and renal cells with 200µM of αKGlogues for 90 and 120 minutes and 
evaluated HIF-1α levels compared to corresponding not-treated cells using western blot analysis. As 
positive control of HIF-1α stabilization, we incubated the same cell lines under normoxic condition 
(21% O2) with 150µM of desferoxamine (DFO), an iron chelator that prevents PHD activity leading 
to HIF-1α accumulation. Further, dimethyl-2-oxoglutarate was used as a further example of αKG 
derivative, commercially available, since it has been shown to successfully permeate across the 
plasma membrane and to increase αKG intracellular levels 
68
.  
Western blot analysis showed that not-treated TPC-1 cells were characterized by a higher capacity 
to stabilize HIF-1α protein levels after 120 minutes under hypoxic condition compared to NTHY 
3.1 cells, highlighting the crucial role of HIF-1α in adaptive responses of the tumor cells to changes 
in oxygen homeostasis (Figure 25A, 25B). As previously shown, high concentration of carrier C 
promoted a cytotoxic effect on NTHY 3.1 independently from αKG, thus the corresponding 
αKGlogue has been excluded this study. NTHY 3.1 and TPC-1 cells were incubated under hypoxic 
condition for 30 minutes, in order to stabilize HIF-1α. After that, cells were incubated with 
αKGlogues for 90 and 120 minutes. No reduction of HIF-1α protein levels was observed in NTHY 
3.1 cells after αKGlogues treatment; rather the hypoxic transcriptional factor seemed to increase its 
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stability over time (Figure 25A, 25C). Conversely, αKGlogues B, D and E were selected for their 
capacity to destabilize HIF-1α specifically in TPC-1 cells already after 90 and 120 minutes of 







In renal models, UOK-257 cancer cells showed an increased capacity to stabilize HIF-1α in hypoxia 
compared to HK-2 normal cells (Figure 26A, 26B), similarly to what observed in thyroid cells. 
Furthermore, αKGlogues E and F showed a specific effect on cancer cells to reduce HIF-1α protein 
levels respectively after 120 and 90 minutes of treatment under hypoxic condition. In addition, 
Figure 25: αKGlogue B, D and E reduce HIF-1α protein levels specifically in thyroid cancer cells under 
hypoxic condition. (A, B) Western blot analysis of HIF-1α levels after treatment with αKGlogues for 90 and 120 
minutes in NTHY 3.1 and TPC-1 cells under hypoxic condition (1% O2). β-Actin was used as loading control. (C, 
D) Densitometric evaluation of HIF-1α. Data were normalized on the corresponding not-treated cells for each time 




αKGlogue G promoted a decrease of HIF-1α stability in both HK-2 and UOK-257 cells after 90 
minutes, but only in UOK-257 cells after 120 minutes (Figure 26A, 26B, 26C, 26D). Thus, based 
on this screening we selected αKGlogues E, F and G for their ability to reduce HIF-1α levels under 








Figure 26: αKGlogue E, F and G are able to destabilize HIF-1α under hypoxic condition in renal cancer cells. 
(A, B) Western blot analysis of HIF-1α levels after treatment with αKGlogues for 90 and 120 minutes in HK-2 and 
UOK-257 cells under hypoxic condition (1% O2). β-Actin was used as loading control. (C, D) Densitometric 
evaluation of HIF-1α. Data were normalized on the corresponding not-treated cells for each time points and on β-




This first phase of the screening had as its main objective to select αKGlogues able to reduce HIF-
1α stability under hypoxic condition in each cell models after short period of intense hypoxia. Once 
the best compounds were identified, we attempted to evaluate how long was the effect on HIF-1α 
levels. Therefore, we treated thyroid and renal cells for 6, 12 and 24 hours with the previously 
selected αKGlogues. The treatment with αKGlogues for 24 hours was performed without changing 
the culture medium or replacing it after 12 hours with fresh medium supplemented with the 
corresponding αKGlogue. For thyroid cells we selected αKGlogue B, D and E that were able to 
reduce HIF-1α protein levels in TPC-1 cells in hypoxia, although did not exert any effects in NTHY 
3.1. Further evaluations of αKGlogue B ability to destabilize HIF-1α protein levels after more long-
term exposure in hypoxia are still ongoing. When NTHY 3.1 cells were exposed to prolonged 
hypoxia, both αKGlogues D and E slightly reduced HIF-1α stabilization compared to corresponding 
untreated cells after 6 hours. Conversely, the treatment for 12 and 24 hours did not alter HIF-1α 
levels (Figure 27A, 27B). The same experiment was performed in TPC-1 cells showing a striking 
reduction of HIF-1α levels when cells were exposed to αKGlogue D for at least 12 hours (Figure 
28A, 28B). In particular, an approximately 3-fold decrease of HIF-1α was observed at incubation 
times 12 hours and 12+12 hours. Hence, the maximum effect to destabilize HIF-1α under hypoxic 
condition in TPC-1 cells was obtained after 12 hours of treatment with αKGlogue D, indicating that 
the timing of drug administration is consistent with a hypothetical therapeutic approach in vivo. 
Instead, αKGlogue E was able to reduce HIF-1α protein levels only after 24 hours, but refreshing 
media after 12 hours of treatment (Figure 28A, 28B). Given this prolonged effect in the time, the 
















Figure 27: Treatment with αKGlogue D and E slightly reduces HIF-1α protein levels after 6 hours in NTHY 
3.1 cells in hypoxia. (A) Western blot analysis of HIF-1α levels after treatment with αKGlogues D and E (200µM) 
for 6, 12, 24 hours in NTHY 3.1 cells under hypoxic condition (1% O2). 12+12h seems that cells were treated for 24 
hours but refreshing media after 12 hours with new corresponding αKGlogue. β-Actin was used as loading control. 












Then we performed this experiment in renal cell models, incubating cancer and non-cancer cells for 
6, 12 and 24 hours with αKGlogue E, F and G, which were that compounds able to destabilize HIF-
1α in UOK-257 cells after 90 and 120 minutes under hypoxic conditions. As already observed, after 
2 hours of treatment these three αKGlogues did not reduce HIF-1α levels in HK-2 cells neither after 
more long-term exposure (Figure 29A, 29B). It was observed a slight reduction of HIF-1α protein 
after treatment with αKGlogue G for 6 hours in hypoxia (Figure 29A, 29B). 
 
Figure 28: αKGlogue D and E show a more-long term effect to destabilize HIF-1α in TPC-1 cells. (A) Western 
blot analysis of HIF-1α levels after treatment with αKGlogues D and E (200µM) for 6, 12, 24 hours in TPC-1 cells 
under hypoxic condition (1% O2). 12+12h seems that cells were treated for 24 hours but refreshing media after 12 
hours with new corresponding αKGlogue. β-Actin was used as loading control. (B) Densitometric evaluation of 











Conversely, αKGlogues E, F and G reduced HIF-1α protein levels after 6 and 12 hours of treatment 
under hypoxic condition in UOK-257 cells (Figure 30A, 30B), indicating that the effect on HIF-1α 
of these compounds was not limited to very short incubation times but can persist up to 12 hours.  
 
Figure 29: No alterations of HIF-1α levels are observed in HK-2 cells after longer treatments with αKGlogue 
E, F and G. (A) Western blot analysis of HIF-1α levels after treatment with αKGlogues E, F and G (200µM) for 6, 
12, 24 hours in HK-2 cells under hypoxic condition (1% O2). 12+12h seems that cells were treated for 24 hours but 
refreshing media after 12 hours with new corresponding αKGlogue. β-Actin was used as loading control. (B, C) 


















Figure 30: αKGlogues E, F and G reduce HIF-1α protein levels under hypoxic condition after 6 and 12 hours 
in UOK-257 cells. (A) Western blot analysis of HIF-1α levels after treatment with αKGlogues E, F and G (200µM) 
for 6, 12, 24 hours in UOK-257 cells under hypoxic condition (1% O2). 12+12h seems that cells were treated for 24 
hours but refreshing media after 12 hours with new corresponding αKGlogue. β-Actin was used as loading control. 




It should be noted that in both renal cells, HIF-1α stability was reduced after 24 hours under 
hypoxic condition compared to 6 and 12 hours, independently from αKGlogues treatments. There 
are evidences in literature supporting a temporal regulation of the HIF-1α and HIF-2α-dependent 
responses. Under conditions of acute hypoxia (i.e. <24 hours stimulation), transactivation of target 
genes occurs primarily through the activation of HIF-1α, whereas following longer periods HIF-2α 
begins to exert more of an influence 
159, 160
. It is possible that in renal cells HIF-1α activity reaches 
its highest levels up to 12 hours to mediate acute responses to hypoxia regulating the activation of 
its target genes. This may also explain the reason why αKGlogues E, F and G were able to 
destabilize HIF-1α protein levels only after 6 and 12 hours of treatment supporting the idea that 
increased αKG intracellular levels induce a psudonormoxic state in HIF-1α dependent tumors. 
In conclusion, all αKGlogues previously selected in both thyroid and renal cancer cells for their 
capacity to reduce HIF-1α levels after short time of incubation (90 and 120 minutes) had shown to 
maintain their effectiveness for longer periods under hypoxia exposure, thus being eligible to be 
considered as potential therapeutic agents. 
αKGlogues reduce the tumorigenic potential of thyroid and renal cancer cells in vitro. 
Once established that αKGlogues were able to exert a long-term effect on HIF-1α under hypoxic 
condition, the next step was to analyze whether the same compounds may display an anti-
tumorigenic potential on thyroid and renal cancer cell in vitro. To this purpose, we performed a 
colony formation assay to test whether treatment with different concentrations of selected 
αKGlogues can reduce the clonogenic properties of tumor cells under hypoxic condition. TPC-1 
cells were incubated with three different concentrations (2µM, 20µM and 200µM) of αKGlogue E 
and D for one week. Despite the long exposure time, treatment with 2µM and 20µM of compounds 
did not affect the ability of TPC-1 to form colonies. Conversely, the TPC-1 clonogenic capacity was 













Then we performed a viability assay treating TPC-1 and NTHY 3.1 cells with 2µM, 20µM and 
200µM of αKGlogue D and E for multiple time points in normoxic and hypoxic conditions. As 
observed in colony formation assay, treatment with 2µM and 20µM of both αKGlogues did not 
alter neither NTHY 3.1 nor TPC-1 cell viability in normoxia, while a significant reduction of cell 
growth was observed treating cells with 200µM of compounds (Figures 32 and 33, panels A and B). 
Similar results were obtained when O2 availability is limited (Figures 32 and 33, panels C and D).   
Figure 31: αKGlogues D and E abolish clonogenic survival of TPC-1 cells. (A) TPC-1 cells were treated for one 
week with 2µM, 20µM and 200µM of αKGlogues D and E under hypoxic condition (1% O2). (B, C) Number of 
colonies were counted using ImageJ software. Data are media ± SEM, n=3. Asterisks represented *** p-value ≤ 











In particular, a reduction of NTHY 3.1 cell proliferation was induced using 200µM of αKGlogue D 
under normoxic and hypoxic condition (Figure 32A, 32C, 34A, 34C). Instead, the same treatment 
promoted the arrest of TPC-1 cell growth, independently from intracellular O2 levels (Figure 32B, 
32D, 34B, 34D). Therefore, the efficacy of αKGlogue D to reduce cell proliferation was greater in 
thyroid cancer cells rather than in normal cells encouraging future investigations regarding its role 
to reduce the tumorigenic potential in vitro through the inhibition of HIF-1α stabilization and 
activity. 
Figure 32: αKGlogue D induces the arrest of TPC-1 cell growth, without having a cytotoxic effect in NTHY 
3.1 cells, independently from O2 levels. (A, B) NTHY 3.1 and TPC-1 cells were grown in increasing dose of 
αKGlogue D (2µM, 20µM and 200µM) for 24, 48 and 72 hours in normoxic condition (21% O2). (C, D) NTHY 3.1 
and TPC-1 cells were grown in increasing dose of αKGlogue D (2µM, 20µM and 200µM) for 24, 48 and 72 hours in 
hypoxic condition (1% O2).  Cell viability was determined using SRB assay. Data (mean ± SEM) are expressed in 
percentage considering as 100% the cell viability at T0 (n=3). Asterisks represented * p-value ≤ 0.05, ** p-value ≤ 










The αKGlogue E promoted NTHY 3.1 cell death using 200µM for 24, 48 and 72 hours both in 
normoxia and hypoxia (Figure 33A, 33C, 34A, 34C). Conversely, a cytostatic effect was observed 
after treatment of TPC-1 cells after 24, 48 and 72 hours (Figure 33B, 33D, 34B, 34D). However, the 
cytotoxicity shown in thyroid normal cells lead us to exclude αKGlogue E from subsequent 
analyses in term of pre-clinical applications. 
 
Figure 33: αKGlogue E induces a non-cancer specific cytotoxic effect at higher concentration in thyroid cells. 
(A, B) NTHY 3.1 and TPC-1 cells were grown in increasing dose of αKGlogue E (2µM, 20µM and 200µM) for 24, 
48 and 72 hours in normoxic condition (21% O2). (C, D) NTHY 3.1 and TPC-1 cells were grown in increasing dose 
of αKGlogue E (2µM, 20µM and 200µM) for 24, 48 and 72 hours in hypoxic condition (1% O2). Cell viability was 
determined using SRB assay. Data (mean ± SEM) are expressed in percentage considering as 100% the cell viability 
at T0 (n=3). Asterisks represented * p-value ≤ 0.05, ** p-value ≤ 0.01 and *** p-value ≤ 0.001 relative to not-












The same set of experiments was performed in renal cell models using αKGlogues previously 
selected to reduce HIF-1α protein levels in hypoxic condition in UOK-257 cells (αKGlogues E, F 
and G) at different concentrations (2µM, 20µM and 200µM). The ability of UOK-257 cells to form 
colonies under hypoxic condition was not altered by the treatment with 2µM and 20µM of 
concentrations. On the contrary, the clonogenic capacity was completely abolished treating UOK-
257 cells with 200µM of αKGlogues E and G, whereas treatment with αKGlogue F was able to 
induce a significant reduction of colony numbers at same concentration (Figure 35A, 35B, 35C, 
35D). αKGlogues E and G showed a greater ability to reduce the tumorigenic potential of UOK-257 
cells in hypoxia compared to αKGlogue F. Therefore, we decided to investigate the effect only of 
the first two αKGlogues on viability assay in renal cancer and non-cancer cells. 
Figure 34: αKGlogues D and E arrest TPC-1 cell proliferation. (A, B) Comparison of the effect of αKGlogue D 
and E to alter NTHY 3.1 and TPC.1 cell growth under normoxic condition (21% O2). Cell were treated with 200µM 
of these αKGlogues for 24, 48 and 72 hours. (C, D) Comparison of the effect of αKGlogue D and E to alter NTHY 
3.1 and TPC.1 cell growth under hypoxic condition (1% O2). Cells were treated with 200µM of these αKGlogues for 
24, 48 and 72 hours. Cell viability was determined using SRB assay. Data (mean ± SEM) are expressed in 
percentage considering as 100% the cell viability at T0 (n=3). Asterisks represented * p-value ≤ 0.05, ** p-value ≤ 






αKGlogues E and G reduced significantly HK-2 and UOK-257 cell proliferation using 200µM of 
concentration, while no alteration of cell growth was observed treating the same cells with 2µM and 
20µM confirming the anti-proliferative effect seen in colony assay experiments at high 
concentration (Figure 36 and 37). HK-2 cell viability was significantly reduced after 24, 48 and 72 
Figure 35: αKGlogues E, F and G impact clonogenic 
survival of UOK-257 cells under hypoxic condition. 
UOK-257 cells were treated for ten days with 2µM, 20µM 
and 200µM of αKGlogues E, F and G. (B, C, D) Number 
of colonies were counted using ImageJ software. Data are 
media ± SEM, n=3. Asterisks represented * p-value ≤ 
0.05, ** p-value ≤ 0.01 and *** p-value ≤ 0.001 relative to 
non-treated cells using Student’s T-test. 
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hours under physiological O2 levels (21% O2) and after 72 hours of treatment with 200µM of 
αKGlogue E under hypoxic condition (Figure 36A, 36C). The incubation with the same compound 
and amount induced a cytostatic effect on UOK-257 cell proliferation in both normoxia and hypoxia 
(Figure 36B, 36D). The αKGlogue G showed the same effect of αKGlogue E to decrease HK-2 cell 
proliferation in different conditions of intracellular O2 tension (Figure 37A, 37C). Conversely, a 
cytotoxic effect was observed already after 24 hours treating UOK-257 cells with 200µM of 
αKGlogue E in normoxia, while a cytostatic effect after 24 and 48 hours followed by cytotoxic 




Figure 36: αKGlogue E significantly reduces UOK-257 cell growth, without having a cytotoxic effect on HK-2 
cells. (A, B) HK-2 and UOK-257 cells were grown in increasing dose of αKGlogue E (2µM, 20µM and 200µM) for 
24, 48 and 72 hours in normoxic condition (21% O2). (C, D) HK-2 and UOK-257 cells were grown in increasing 
dose of αKGlogue E (2µM, 20µM and 200µM) for 24, 48 and 72 hours in hypoxic condition (1% O2). Cell viability 
was determined using SRB assay. Data (mean ± SEM) are expressed in percentage considering as 100% the cell 
viability at T0 (n=3). Asterisks represented * p-value ≤ 0.05, ** p-value ≤ 0.01 and *** p-value ≤ 0.001 relative to 










Therefore, both αKGlogues were able to induce a growth slowdown in HK-2 cells compared to 
untreated cells under normoxia and hypoxia, though without showing an arrest of cell proliferation 
(Figure 38A, 38C). In renal cancer cells, the cell viability was reduced ~7-fold compared to not-
treated cells after incubation with αKGlogues E and G for 72 hours in hypoxia inducing an arrest of 
UOK-257 cell growth (Figure 36D, 37D, 38D). Under normoxic condition, αKGlogues E promoted 
the same effect shown in hypoxia; conversely, αKGlogues G induced cell death already after 24 
hours of incubation. In fact, in this latter case, the number of cells still proliferating went down the 
100%, considered as the amount of cancer renal cells seeded before the incubation with αKGlogue 
G (Figure 38B). In conclusion, αKGlogues E and G had demonstrated to be both good candidates to 
Figure 37: αKGlogue G treatment promotes UOK-257 cell death. (A, B) HK-2 and UOK-257 cells were grown 
in increasing dose of αKGlogue G (2µM, 20µM and 200µM) for 24, 48 and 72 hours in normoxic condition (21% 
O2). (C, D) HK-2 and UOK-257 cells were grown in increasing dose of αKGlogue G (2µM, 20µM and 200µM) for 
24, 48 and 72 hours in hypoxic condition (1% O2). Cell viability was determined using SRB assay. Data (mean ± 
SEM) are expressed in percentage considering as 100% the cell viability at T0 (n=3). Asterisks represented * p-




be used as therapeutic approach to decrease the renal cancer cells tumorigenic potential, without 














Figure 38: αKGlogues E and G reduce UOK-257 tumorigenic potential in vitro. (A, B) Comparison of the effect 
of αKGlogue E and G to alter HK-2 and UOK-257 cell growth under normoxic condition (21% O2). Cell were 
treated with 200µM of these αKGlogues for 24, 48 and 72 hours. (C, D) Comparison of the effect of αKGlogue E 
and G to alter HK-2 and UOK-257 cell growth under hypoxic condition (1% O2). Cells were treated with 200µM of 
these αKGlogues for 24, 48 and 72 hours. Cell viability was determined using SRB assay. Data (mean ± SEM) are 
expressed in percentage considering as 100% the cell viability at T0 (n=3). Asterisks represented * p-value ≤ 0.05, 




Overall, the screening performed in this study led to select αKGlogue D in thyroid cells and 
αKGlogues E and G in renal cells (Table 4). Further investigations will be required to identify the 
molecular mechanism through which these ester derivatives of αKG exerted their anti-tumorigenic 
potential by promoting a pseudonormoxic condition in HIF-1-dependent cancer cells. 
 
Cell model αKGlogue selected Effect observed 
Thyroid cells αKGlogue D - Not cytotoxic for N-THY 3.1 
- Inhibition of TPC-1 cell proliferation and 
clonogenic capacity in vitro 
- Decreased HIF-1α stability after 12h in hypoxic 
condition in TPC-1 cells 
Renal cells αKGlogues E and G - Not cytotoxic for HK-2 
- Inhibition of UOK-257 cell proliferation and 
clonogenic capacity in vitro 



















Table 4: αKGlogues selected for their ability to reduce HIF-1α protein levels under hypoxic condition and the 





The hypoxic tumor microenvironment is subjected to HIF-driven transcriptional response that 
induces the activation of genes that are involved in crucial aspects of cancer biology, including 
angiogenesis, cell survival, glucose metabolism and invasion. This leads cancer cells to acquire 
properties that allow them to overcome the lack of energy and nutrients supply within hypoxic 
niches. In this scenario, the transcriptional factor HIF-1α is the main molecular player involved in 
the early stage of hypoxic response orchestrating these metabolic and genetic changes in cancer 
cells which are correlated with poor prognosis in oncological patients. Thus, the idea to target HIF-
1α is an attractive therapeutic strategy to downregulate tumor aggressiveness interfering with cancer 
cells metabolism and tumor growth.  
HIF-1α stability and activity are finely regulated by intracellular O2 levels, but, at the same time, 
several studies revealed the existence of alternative cellular players and molecular pathways able to 
affect HIF-1α stability by modulating PHDs activity independently from O2 levels 
34
. In line with 
this, tumors harboring SDH, FH and IDH1/2 mutations are able to stabilize HIF-1α in normoxia as 
consequence of SA, fumarate and 2-HG accumulation that play as allosterically inhibitors of PHDs 
enzymatic reaction 
48, 49, 50
. Furthermore, 2-HG is also a competitive inhibitor of TETs and KDMs, 
others αKG-dependent dioxygenase as well as PHDs, and high levels of this oncometabolite may 
alter the epigenetic landscape of cancer cells 
53, 161, 162
. Similarly, recent studies have revealed that 
together with 2-HG, SA and fumarate can also induce alterations in DNA and histones methylation, 
thus enhancing cancer formation 
53, 163, 58, 60
. Conversely, increased cytosolic concentrations of αKG 
have a role to reverse the methylation status of both histones and DNA 
164
. Moreover, as co-
substrate of PHDs, high αKG intracellular levels enhance the PHDs affinity for O2 and feed their 
hydroxylation reaction preventing HIF-1α stabilization also in hypoxia 
165, 51, 52
. In fact, the 
estimated Km of PHDs for αKG is ∼50 μM indicating that these enzymes are greatly sensitive to 
αKG oscillations 
35, 36
. Accordingly, our group has demonstrated that the imbalance of αKG/SA 
ratio, towards αKG, was related to the NADH accumulation, due to the inhibition of αKG 
dehydrogenase, in CI-deficient cells. This alteration of TCA cycle metabolites levels, as 
consequence of severe mutations that impair respiratory CI activity and assembly, hampered tumor 
growth promoting the chronic activation of PHD, even al low O2 levels, and consequent HIF-1α 




. Furthermore, these data indicated that respiratory CI is essential for the hypoxic adaptation of 
cancer cells and may be considered as an interesting target for development of new anti-cancer 
69 
 
therapies. Indeed, in the last few years several mitochondrial CI inhibitors have been shown to share 
the ability to destabilize HIF-1α and prevent hypoxic adaptation in cancer cells 
93
. 
Supported by these findings, the main aim of this project was to identify novel and safe adjuvant 
therapeutic agents for aggressive cancers for which adaptation to hypoxia is a necessary step to 
progress toward malignancy. To this aim, we attended to prove that HIF-1α destabilization and 
pseudonormoxia can be pharmacologically induced by increasing αKG levels indirectly using CI 
inhibitors or directly through cell permeable αKG ester derivatives.  
To identify novel molecules that specifically impair mitochondrial CI activity and destabilize HIF-
1α under hypoxic condition, we took advantage by the collaboration with Khondrion, a Dutch 
company located in Nijmegen primarily focused on the development of innovative therapies for 
inherited mitochondrial diseases. We screened a panel of six KH-compounds to identify novel 
molecules able to hamper tumor growth through the specific inhibition of respiratory CI activity. In 
this regard, KH412, KH474 and KH0-B were firstly selected for their ability to reduce the 
tumorigenic potential of thyroid cancer cells in vitro, and for their safety toward non-cancer cells 
consistent with a hypothetical therapeutic approach. However, although these molecules reduced 
the protein levels of several CI subunits (NDUFA9, NDUFS3 and NDUFB8) in thyroid cancer 
cells, none of them interfered with the physiologic activity of mitochondrial CI. Furthermore, 
treatment with KH412, KH474 and KH0B induced also a lower protein expression of VDAC and a 
reduction of SDHA protein levels was observed after treatment with KH474 in isolated 
mitochondria from thyroid cancer cells. Therefore, it is plausible to hypothesize that the anti-
tumorigenic activity of these three KH-compounds may affect mitochondrial biogenesis, respiratory 
complexes stability or stimulate mitophagy, without exerting a specific effect on CI activity. 
Despite Warburg effect, cancer cells also need mitochondrial respiration to provide the building 
blocks for macromolecule (nucleotides, lipids and amino acids) biosynthesis as well as ATP and 
NADPH, which are essential to acquire a proliferative advantage 
166
. In fact, it was demonstrated 
that enhanced mitochondrial biogenesis is often correlated with cancer cells capacity to grow 
anchorage independently, invasiveness and metastasis migration 
167, 168
. In this regard, the 
development of new molecules that show the ability to inhibit mitochondrial biogenesis in cancer 
cells could represent a new therapeutic approach. On the other hand, the anti-tumorigenic potential 
of KH412, KH474 and KH0B may be also due to their ability to stimulate mitophagy. Mitophagy 
can have the beneficial effect by eliminating old and/or damaged mitochondria, thus maintaining 
the integrity of the mitochondrial pool. However, mitophagy is not only limited to the turnover of 
dysfunctional mitochondria but also promotes reduction of overall mitochondrial mass in response 
to certain stresses, such as hypoxia and nutrient starvation 
169
. This prevents generation of reactive 
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oxygen species and conserves valuable nutrients from being consumed inefficiently, thereby 
promoting cellular survival under conditions of energetic stress 
169
. In this context, tumor cells are 
strictly dependent on functional mitophagy to preserve their malignant phenotype and dysregulation 
of this process may represent a therapeutic strategy to hinder tumor progression. However, further 
studies are required to better investigate the possible correlation between the anti-tumorigenic 
activity of KH412, KH474 and KH0B and the impact on mitochondrial biogenesis or altered 
mitophagy, that was out of the topic of this project.  
Hence, we decided to focus our study on others potential CI inhibitors. A large panel of molecules 
has been studied as anticancer drugs for their capacity to pharmacologically inhibit CI function. It is 
demonstrated that rotenone, piericidin A and capsaicin induced cancer cells death under metabolic 
stress condition acting as specific CI inhibitors. Nevertheless, the use of these molecules remains 
confined into preclinical studies since they shown to stimulate ROS production thus being cytotoxic 
125
. Recently, biguanides have been recognized as a new class of CI inhibitors, preventing 
ubiquinone reduction in a non-competitive manner 
132
. In particular, several studies have revealed 
that metformin administration, already used as clinical approach for type 2 diabetes mellitus, was 
correlated with lower risk to develop cancer and, at the same time, with a better prognosis in 
oncologic patients 
129, 130, 131
. However, the molecular mechanism trough which metformin might 
act as anti-cancer agent is still unclear and appears to be related to the combination of intracellular 
and systemic effects. It is reported that metformin decreased tumor growth by reducing circulating 




. Others works ascribed anticancer proprieties of metformin to its ability to activate the cell 
energy sensor AMPK and consequent inhibition of the mammalian target of rapamycin complex 1 
(mTORC1), which plays a pivotal role in metabolism, growth and proliferation 
172, 173
. However, 
this last mechanism cannot exclusively explain the anti-tumorigenic effect of metformin since many 
cancers unable to activate AMPK are still susceptible to these drugs. Recently, a growing number of 
studies demonstrated that metformin may exert its anti-proliferative and cytostatic effect in cancer 







. Therefore, we investigated the effect of this drug in CI-deficient cells 
compared to isogenic CI-competent counterparts and we observed that metformin mostly reduced 
osteosarcoma cell proliferation in vitro independently from the presence of functional respiratory 
CI. Indeed, the difference between CI-competent and CI-null cells in terms of reduced cell 
proliferation was only about 20%, suggesting that other mechanisms prevail in the cytostatic effect 
of metformin. Furthermore, it should be noted that metformin-dependent inhibition of CI decreased 
cell proliferation, but not increasing cell death. Our data were consistent with what observed by 
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Griss and co-workers regarding the dose-dependent cytostatic effects of metformin exerted on 
cancer cell proliferation, but without showing major alterations in cell viability 
142
. Despite the 
importance of Warburg profile for cancer cells, it is now known that, to sustain and fuel 
tumorigenesis, oxidative metabolism can be re-established and a significant level of OXPHOS 
activity is maintained in cancer cells 
174, 175
. The arrest off cell growth, rather than an increase of 
cell death, it was a consequence of mitochondrial CI inhibition and OXPHOS impairment after 
metformin administration which leading cancer cell to rely more or exclusively on glycolysis to 
sustain their proliferation 
135, 133
. In fact, it was demonstrated that glycolysis inhibition in 
metformin-treated cells can lead to metabolic crisis enhancing its anti-proliferative effect 
176
. In 
parallel, there are evidences regarding the cytostatic effects of metformin as consequence of a 
reduced glucose- and glutamine-dependent anaplerotic flux into the TCA cycle which in turn 
impacts pathways of mitochondrial-dependent biosynthesis including citrate-dependent de novo 
lipogenesis 
142
. In this scenario, metformin could hamper tumor progression by decreasing the 
availability of several TCA intermediate metabolites essential for tumor cells proliferation. The 
cytostatic effect induced by metformin through CI inhibition is similar to the unconventional case of 
oncocytic tumors, a subset of epithelial neoplasms, in which the occurrence of high load of CI-
destructive mtDNA mutations have been associated with more benign state of quiescence, typical of 
oncocytomas 
177
. The severe OXPHOS deficiency forces oncocytic cells to adopt alternative 
metabolic pathways such as increased glycolysis to compensate for ATP production. However, the 
NAD
+
/NADH unbalance impacts the shift from respiration to glycolysis in cancer 
178
. Indeed, 
severe CI damage was shown to induce NADH accumulation, which is a known inhibitor of several 
TCA cycle enzymes, such as pyruvate dehydrogenase complex, citrate synthase, and αKG 
dehydrogenase complex. Consequently, oncocytic tumors have been related with accumulation of 
same TCA cycle metabolites, as αKG, promoting HIF-1α destabilization even during normoxia and 
preventing the Warburg effect and the progression to a malignant state 
39
. In this frame, several 
studies have demonstrated that also metformin administration was related with the inhibition of 







. In contrast to other CI inhibitors, metformin did not stimulate H2O2 production 
preventing in this way HIF-1α stabilization and activity 
133, 179
.  
Since we were interested in finding CI inhibitors that may have a clinical use in order to destabilize 
HIF-1α in hypoxic cancer cells, we decided to investigate the effect of metformin on HIF-1α protein 
levels in osteosarcoma CI-competent cell models. Although the specific CI inhibitor effect did not 
seem to be the main molecular mechanism by which metformin decreased the tumorigenic potential 
of cancer cells not CI-deficient in vitro, a reduction of HIF-1α levels was observed treating these 
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cells under hypoxic condition. It is known that metformin treatment stimulated an increase of PHDs 
levels in hypoxia inducing the reduction of HIF-1α stability and nuclear localization 
145
. Further, 
Griss and co-workers demonstrated that metformin treatment significantly lowered all metabolites 
of the TCA cycle except αKG, whose increased levels allosterically foster PHDs activity 
independently from intracellular O2 availability 
142, 51, 52
. Thus, it is possible to hypothesize that in 
osteosarcoma cells treatment with metformin may boost PHDs activity, upon CI inhibition and 
consequent intracellular αKG accumulation, promoting HIF-1α destabilization under hypoxic 
conditions. On the other hand, as described by Prior and colleague, CI inhibition reduced the 
intracellular oxygen consumption leading to a condition of intracellular normoxia even when the 
extracellular oxygen tension is low 
141
. In line with this, it was demonstrated that metformin 
efficiently reduced mitochondrial respiration by inhibiting respiratory CI in hepatocellular 
carcinoma and the decrease of mitochondrial oxygen consumption was correlated to HIF-1α protein 
degradation 
179
. In this scenario, the use of metformin could open the doors to alternative 
therapeutic strategy to contrast hypoxic adaptation of cancer cells through respiratory CI inhibition. 
Besides the specificity towards mitochondrial CI, we were also interested to evaluate the efficiency 
of metformin to reduce the tumorigenic potential in cancer cells considering, at the same time, its 
effect on non-cancer cells. In this regard, we have reported that metformin administration promoted 
a reduction of thyroid cancer cells proliferation under hypoxic condition, while no effects were 
observed at physiological O2 levels (21% O2). Conversely, changes in O2 availability and metformin 
treatment did not alter thyroid non-cancer cells viability. These data indicated that metformin 
exerted a specific anti-cancer activity in hypoxia. Our findings are supported by recent Safari and 
colleagues work, in which it is demonstrated that metformin enhanced its anti-tumor effect under 
hypoxia condition rather than normoxia in breast cancer cells, without showing side effects on non-
cancer cells in the same conditions 
180
. In this regard, the microenvironment of cancer cells is 
different from that of non-cancer cells due to their high proliferation rate and lower energy 
supplements by nutrient circulation 
181
. Therefore, cancer cells alter their metabolic pathways to 
survive and, unlike non-cancer cells, may adapt better to drastic changes in oxygen availability 
181
. 
The different metabolism may be the key to explain the specific anti-cancer effect of metformin 
induced under hypoxic condition. Concordantly, we also demonstrated that thyroid cancer cells are 
characterized by a higher capacity to accumulate and stabilize HIF-1α in hypoxia compared to non-
cancer cells. This may justify the lower sensitivity of NTHY 3.1 cells to metformin treatment. 
However, adding complexity, the enhanced anti-tumor effect shown after metformin treatment 
under hypoxia in thyroid cell models was not confirmed using renal cells models. In this case, 
metformin treatment did not alter renal cell viability neither depending on cancer or non-cancer 
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nature nor depending on O2 levels. These data confirmed the absence of side effect in normal cells 
after metformin treatment and suggested an anti-tumorigenic effect dependent on tissue origin and 
type of tumors. Indeed, UOK-257 is a cell line derived from human renal carcinoma of Birt-Hogg-
Dubé (BHD) patient and are characterized by higher dependency on glucose metabolism, which is a 
common feature of insulin resistance 
158
. These findings may explain the not efficacy of metformin 
to decrease renal cancer cell proliferation after 72 hours of treatment. However, long-term exposure 
to metformin significantly reduced UOK-257 clonogenic capacity in vitro suggesting that this drug 
might require a specific time to be effective in preventing renal cancer cell growth. In line, 
metformin treatment was related to a reduction of HIF-1α protein levels under hypoxic condition 
only after 24 hours in renal cancer cells, while in both osteosarcoma and thyroid cancer models 
HIF-1α was destabilized already after 2 hours of treatment. These data suggested that systemic 
effect or effects dependent from multiple molecular player may mainly concur to anti-cancer 
metformin proprieties. To support this hypothesis further studies will be required using a large 
panel of different cell models. 
In the last few years, an increasing number of works has emphasized the role of CI inhibitors to 
interfere with HIF-1α stability acting as anti-proliferative and anti-cancer agent and opening the 
door to new possible therapeutic approaches for solid tumors, since mitochondrial function and 
adaptation to hypoxia are necessary for tumor progression. However, it is important to consider the 
double-edged role of respiratory CI in cancer. This metabolic enzyme actively controls the cellular 
energetic and redox balance, providing a crucial checkpoint of cell metabolism, proliferation and 
survival. For these reasons, it is crucial to characterize the molecular mechanisms through which 
metformin, as others CI inhibitors, may influence and humper tumor progression. Further 
investigations are necessary to clarify these points and to identify compounds that are safe enough 
to act selectively on cancer cells without drastic side effects. 
An alternative and more direct approach to destabilize HIF-1α in hypoxic cancer cells by promoting 
PHDs enzymatic activity was represented by the use of αKGlogues. Recent studies have brought to 
light the pleiotropic anti-tumor activity of αKG. This TCA metabolite is involved in various cellular 
mechanisms in which changes of its intracellular levels might exert an impact in the regulation of 
signaling pathways engaged in promotion of carcinogenesis 
182
. As a Krebs cycle metabolite, it 
regulates anabolic and catabolic TCA products and substrates, thereby regulating amino acid 
synthesis, ATP production, and reducing equivalent (NAD
+
/NADH) generation, which in turn can 
influence ROS levels. In this regard, it has been shown that the αKG molecule positively modulates 
antioxidant enzyme activity in rats during induced hepatocarcinogenesis, restoring the oxidation-
reduction homeostasis 
183, 184
. Additionally, altered αKG levels may promote epigenetic 
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modifications by altering the activity of enzymes involved demethylation/hydroxylation reactions 
which belong to the family of αKG-dependent dioxygenases 
182
.  
Concerning the role of this TCA cycle metabolite to prevent hypoxic adaptation of cancer cells, 
Gottlieb and his group have shown that the increase in αKG levels is sufficient to oppose hypoxia-
mediated activation of HIF1α in SDH-deficient and FH-deficient tumors by promoting chronic 
PHDs enzymatic activity and consequent HIF-1α hydroxylation and destabilization even at low 
oxygen levels 
51, 52
. Treatment with esters of αKG not only decreased HIF-1α protein levels and the 
expression of its target genes, but also reduced glucose up-take and lactate production suggesting a 
decrease in glycolytic flux. In these conditions, cells were less able to use oxygen to synthetizes 
ATP and an increase of cell death was observed in xenograft tumors 
185
. In the light of the positive 
contribution of increasing αKG intracellular levels to reduce tumor survival and progression, the 
experimental approach to target tumor hypoxia via PHDs may represent a valid tool for cancer 
therapy. In this research field, our group has generated a library of novel αKGlogues that induced a 
more long-term effect on HIF-1α compared to others membrane-permeating ester of αKG, without 
having a cytotoxic effect on non-cancer cells. 
To this purpose, αKG was conjugated with different hydrophobic carriers, which allow it to cross 
the plasma membrane and accumulate into the cytosol. Same of these carriers were characterized by 
own anti-tumorigenic activity and, accordingly, they have been evaluated for their possible 
synergic/antagonist effect with αKG to reduce the tumorigenic potential in vitro and for their 
cytotoxicity. However, the cell susceptibility to these treatments was strictly dependent to their 
tissue origin. This brought out the difficulty to develop an anti-cancer therapy that, besides to be 
considerate safe for normal cells, has to face with the problematic of the heterogeneity intra- and 
inter-tumor. 
Afterwards, all αKGlogues synthetized were screened for their ability to destabilize HIF-1α protein 
levels under hypoxic condition. The first step of the screening has provided for a short exposure to 
different αKGlogues treatment in order to determine which compounds effectively reduced HIF-1α 
stability in thyroid and renal cell models. The αKGlogues selected were further evaluated for their 
capacity to induce a pseudonormoxic state in hypoxic cells after more long-term treatment leading 
to identify in thyroid and renal cells respectively αKGlogue D and αKGlogues E and G as novel and 
safe adjuvant therapeutic agents able to pharmacologically induce a pseudonormoxic state in 
hypoxic cancer cells. It is important to underline that these molecules were selected for their 
capacity to significantly reduce the tumorigenic potential of thyroid and renal cancer cells in vitro, 
without being cytotoxic for non-cancer cells counterpart. In this context, we also demonstrated that 
αKGlogues concentrations lower than 200µM, i.e. 2µM and 20µM, did not alter thyroid and renal 
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cell viability probably because the intracellular concentration of αKG was not sufficient to trigger 
chronic PHDs activity. Accordingly, as already said, the estimated Km of PHDs is ∼50μM 
indicating that αKGlogues should be administrated using concentrations higher that this value to 
induce a pseudormoxic state in hypoxic cancer cells 
35, 36
. 
Furthermore, the effect on HIF-1α of these αKGlogues was not limited to very short incubation 
times but can persist up to 12 hours under hypoxic condition. Therefore, αKGlogues selected in our 
laboratory were able to exert a more long-term effect on HIF-1α commensurate with a potential 
clinical treatment in human patients using a concentration 10 times lower compared to the αKG 
derivatives used by Tennent and colleague. As a future perspective, it would be intriguing to prove 
the ability of these compounds to chronically destabilize HIF-1α by promoting PHDs activity in cell 
system that mimics the complex architecture and functional and metabolic heterogeneity of cancer 
cells in vivo. In this regard, the use of 3D cell culture may be advantageous in providing more 
physiologically relevant information and more predictive data for further in vivo tests. However, 
this PhD project has allowed us to collect several data which are promising in term of the 
development of a metabolic approach able to impinge the aggressiveness of hypoxic cancer cells. In 
this context, our experimental approach to trigger the intracellular increase of αKG levels may 
represent a valid strategy to allosterically boost PHDs enzymatic function and thus to prevent 
hypoxic adaptation. 
Overall, the indirect respiratory CI inhibition and the direct use of αKGlogues may have a potential 
role to prevent hypoxic adaptation and metabolic reprogramming of cancer cells miming a 
normoxic condition. The consequent inability to adapt to adverse environmental conditions leads to 
a significant delay in tumor progression opening the doors to additional pharmacological 
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